
<html lang="en"     class="pb-page"  data-request-id="51850b63-86a1-46be-9092-810a08f4c6ff"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2010.53.issue-7;ctype:string:Journal Content;article:article:10.1021/jm901877j;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor" /></meta><meta name="dc.Creator" content="Vijaykumar G.  Pawar" /></meta><meta name="dc.Creator" content="Martin L.  Sos" /></meta><meta name="dc.Creator" content="Haridas B.  Rode" /></meta><meta name="dc.Creator" content="Matthias  Rabiller" /></meta><meta name="dc.Creator" content="Stefanie  Heynck" /></meta><meta name="dc.Creator" content="Willem A. L.  van Otterlo" /></meta><meta name="dc.Creator" content="Roman K.  Thomas" /></meta><meta name="dc.Creator" content="Daniel  Rauh" /></meta><meta name="dc.Description" content="The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation ..." /></meta><meta name="Description" content="The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 11, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm901877j" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm901877j" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm901877j" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm901877j" /></link>
        
    
    

<title>Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm901877j" /></meta><meta property="og:title" content="Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0006.jpeg" /></meta><meta property="og:description" content="The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation of a series of 6- and 7-substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR. Quinolines 3a and 3e were found to be highly active kinase inhibitors in biochemical assays and were further investigated for their biological effect on EGFR-dependent Ba/F3 cells and non-small cell lung cancer (NSCLC) cell lines." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm901877j"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm901877j">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm901877j&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm901877j&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm901877j&amp;href=/doi/10.1021/jm901877j" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 2892-2901</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm901858n" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm901532h" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vijaykumar+G.++Pawar">Vijaykumar G. Pawar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+L.++Sos">Martin L. Sos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haridas+B.++Rode">Haridas B. Rode</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthias++Rabiller">Matthias Rabiller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefanie++Heynck">Stefanie Heynck</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Willem+A.+L.++van+Otterlo">Willem A. L. van Otterlo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roman+K.++Thomas">Roman K. Thomas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Rauh">Daniel Rauh</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Gleueler Strasse 50, 50931 Köln, Germany</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department I of Internal Medicine and Center of Integrated Oncology Köln—Bonn, University of Köln, 50924 Köln, Germany</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: +49 (0)231-9742 6480. Fax: +49 (0)231-9742 6479. E-mail: <a href="/cdn-cgi/l/email-protection#264247484f434a085447534e66454145084b5641084243"><span class="__cf_email__" data-cfemail="86e2e7e8efe3eaa8f4e7f3eec6e5e1e5a8ebf6e1a8e2e3">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm901877j&amp;href=/doi/10.1021%2Fjm901877j" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 2892–2901</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 11, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 December 2009</li><li><span class="item_label"><b>Published</b> online</span>11 March 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm901877j" title="DOI URL">https://doi.org/10.1021/jm901877j</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2892%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DVijaykumar%2BG.%2BPawar%252C%2BMartin%2BL.%2BSos%252C%2BHaridas%2BB.%2BRode%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D7%26contentID%3Djm901877j%26title%3DSynthesis%2Band%2BBiological%2BEvaluation%2Bof%2B4-Anilinoquinolines%2Bas%2BPotent%2BInhibitors%2Bof%2BEpidermal%2BGrowth%2BFactor%2BReceptor%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2901%26publicationDate%3DApril%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm901877j"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3721</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">37</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm901877j" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Vijaykumar&quot;,&quot;last_name&quot;:&quot;G. Pawar&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;L. Sos&quot;},{&quot;first_name&quot;:&quot;Haridas&quot;,&quot;last_name&quot;:&quot;B. Rode&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;Rabiller&quot;},{&quot;first_name&quot;:&quot;Stefanie&quot;,&quot;last_name&quot;:&quot;Heynck&quot;},{&quot;first_name&quot;:&quot;Willem&quot;,&quot;last_name&quot;:&quot;A. L. van Otterlo&quot;},{&quot;first_name&quot;:&quot;Roman&quot;,&quot;last_name&quot;:&quot;K. Thomas&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Rauh&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;2892-2901&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm901877j&quot;},&quot;abstract&quot;:&quot;The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation of a series of 6- and 7-substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR. Quinolines 3a and 3e were found to be highly active kinase inhibitors in biochemical assays and were further investigated for their biological effect on EGFR-dependent Ba/F3 cells and non-small cell lung cancer (NSCLC) cell lines.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901877j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901877j" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901877j&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901877j" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901877j&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901877j" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm901877j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901877j&amp;href=/doi/10.1021/jm901877j" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm901877j" /></input><a href="/doi/pdf/10.1021/jm901877j" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm901877j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm901877j%26sid%3Dliteratum%253Aachs%26pmid%3D20222733%26genre%3Darticle%26aulast%3DPawar%26date%3D2010%26atitle%3DSynthesis%2Band%2BBiological%2BEvaluation%2Bof%2B4-Anilinoquinolines%2Bas%2BPotent%2BInhibitors%2Bof%2BEpidermal%2BGrowth%2BFactor%2BReceptor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D7%26spage%3D2892%26epage%3D2901%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291264" title="Kinase inhibitors">Kinase inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290795" title="Quinolines">Quinolines</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation of a series of 6- and 7-substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR. Quinolines <b>3a</b> and <b>3e</b> were found to be highly active kinase inhibitors in biochemical assays and were further investigated for their biological effect on EGFR-dependent Ba/F3 cells and non-small cell lung cancer (NSCLC) cell lines.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The tyrosine kinase epidermal growth factor receptor (EGFR<a class="ref internalNav" href="#fn9" aria-label="a">a</a><div class="NLM_fn" id="fn9">a<p class="last">Abbreviations: EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; HTRF, homogeneous time-resolved fluorescence; NSCLC, non-small cell lung cancer; GI<sub>50</sub>, concentration at which 50% growth retardation is observed.</p></div>) and its closely related family member HER2 are recognized targets for targeted cancer therapy and have been extensively investigated by both academia and industry.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Since the 1980s, when EGFR and HER2 were proposed as potential anticancer targets, small molecule kinase inhibitors and monoclonal antibodies have emerged as promising strategies to inhibit EGFR and HER2 kinase activity.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> To date, the Food and Drug Administration has approved 11 small molecule kinase inhibitors for targeted cancer therapy<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and dozens are currently in clinical trials. Out of these 11 inhibitors, Gefitinib, Erlotinib, and Lapatinib (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) belong to a class of 4-anilinoquinazolines which have been designed to target the ATP binding pocket of the kinase domain and are approved for the treatment of EGFR/HER2-dependent tumors which occur in non-small cell lung cancer (NSCLC) or breast cancer.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Although a plethora of quinazoline-based kinase inhibitors are known and widely used in medicinal chemistry and chemical biology research, examples of type I kinase inhibitors based on the closely related quinoline scaffold are few in number.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 4-anilinoquinazoline- and 4-anilinoquinoline-based EGFR/HER2 inhibitors. Simple 4-anilinoquinazolines such as <b>1</b> served as starting points for the development of potent type I and type II EGFR/HER2 inhibitors approved for the treatment of NSCLC. Erlotinib and Gefitinib are type I inhibitors and bind to the ATP site of activated kinases. Lapatinib is a type II inhibitor and stabilizes enzymatically inactive kinase conformations of EGFR and HER2. According to earlier studies, quinolines such as <b>2a</b> show reduced activity against EGFR and are less suited for compound optimization.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a><b>2b</b> represents a series of 6- and 7- substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR discussed in this study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Type I inhibitors are ATP competitive and bind to the hinge region of the enzymatically active kinase domain and represent the prototypical kinase inhibitor. One of the first extensive SAR studies on type I inhibitors active on EGFR was published in 1995 by researchers at Parke-Davis<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> in which Rewcastle and colleagues reported a SAR study on a series of compounds derived from ten-membered nitrogen-containing bicyclic scaffolds. They concluded that the quinazoline core was the best scaffold for the development of EGFR inhibitors because any alteration of the nitrogen substitution pattern in the bicyclic ring resulted in less active compounds.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In particular, the replacement of the N3 of the quinazoline <b>1</b> by a CH resulted in a 200-fold drop in affinity (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). At the same time, based on modeling studies, scientists at Wyeth<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> hypothesized that the quinazoline N3 interacts with the kinase domain via a water-mediated hydrogen bond to the side chain of the gatekeeper Thr790 of EGFR and provided a rationalization for the crucial role of N3 of the quinazoline core for activity (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>a). On the basis of these findings, Wissner et al.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> developed a series of compounds where the N3 of the quinazoline was replaced by a C−CN group to: (a) displace the hypothetical water molecule and (b) to serve as a hydrogen bond acceptor for the Thr790 hydroxyl group (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>b,c). Through this elegant application of a bioisostere, Wissner and colleagues were not only able to generate potent inhibitors of EGFR (e.g. Neratinib, currently in clinical trials) but also to resolve overlapping patent applications with Parke-Davis. This binding mode of quinazolines to the hinge region of the kinase domain and the interaction of N3 with the side chain of the gatekeeper Thr790 via a water molecule was coined in 2002 when researchers at Genentech published the crystal structure of EGFR in complex with Erlotinib (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>)<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and has since then served as an important reference for the structure-based design of both reversible and irreversible EGFR and HER2 kinase inhibitors.<a onclick="showRef(event, 'ref7 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref9 ref10 ref11">(7, 9-11)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding modes of 4-anilinoquinazoline- and 4-anilinoisoquinoline-based EGFR and HER2 inhibitors. (a) Proposed binding mode of a 4-anilinoquinazoline to the ATP-binding site of EGFR. Hydrogen bonding interactions of the inhibitor with the hinge region (pink) and the side chain of the gatekeeper residue Thr790 (mediated via a water molecule (W)) are shown as red dotted lines. (b) This binding mode stimulated the design and synthesis of 3-quinolinecarbonitriles to displace the proposed water molecule and to form a direct hydrogen bond to the side chain of gatekeeper residue (Thr790).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (c) The presence of a less conserved Cys at the lip of the ATP pocket fostered the development of irreversible quinazoline and isoquinoline EGFR inhibitors currently in clinical trials. The irreversible inhibitor Neratinib is modeled to the catalytic domain of EGFR. Modeling is based on the crystal structure of Neratinib in complex with drug resistant EGFR-Thr790Met (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV">2JIV</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The electrophile of the inhibitor forms a covalent bond with the side chain of Cys797. Cys797 is located at the N-terminal end of a short helix and activated by the helix dipole. Both reversible and irreversible 3-quinolinecarbonitriles were designed to (a) displace the water molecule (W10), and (b) to form a direct hydrogen bond to the side chain hydroxyl of the gatekeeper Thr790.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In our studies of the inhibition of EGFR and clinically relevant drug resistant mutant variants by reversible and irreversible 4-anilinoquinazolines,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> we could not correlate the importance of the discussed water-mediated hydrogen bond with potent inhibition of EGFR. This stimulated our interest in designing and synthesizing of a series of 6,7-substituted 4-anilinoquinolines to compare SAR with their direct quinazoline-based homologues and to investigate their inhibition of EGFR and its clinically relevant mutant variants, both in biochemical and in cellular assays.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06326" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06326" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The design and synthesis of the quinoline inhibitors evolved from our previous studies aimed to address questions of how to overcome Thr790Met drug resistance in EGFR using small organic molecules.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> One of the key challenges in targeted cancer therapy is the emergence of drug resistance mutations in the primary target. At the gatekeeper position, mutations leading to sterically demanding amino acids have been observed in BCR/ABL (Thr315Ile), c-KIT (Thr670Ile), the platelet-derived growth factor receptor-α (PDGFRα, Thr674Ile), and EGFR (Thr790Met). All of them result in tumor drug resistance.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> In wild type kinases, the gatekeeper residue is a smaller amino acid located in the hinge region of the kinase domain and controls access to the hydrophobic subpocket, thereby playing a crucial role in inhibitor affinity and selectivity (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> It has also been shown that these mutations prevent binding of kinase inhibitors such as Imatinib, Gefitinib, and Erlotinib due to steric hindrance and/or an increase in ATP affinity,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> highlighting the necessity for the development of novel strategies to design inhibitors capable of overcoming mutation-associated drug resistance in kinases.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Our previous structural and functional studies alluded toward the possibility of a steric clash between the Met gatekeeper in drug resistant EGFR-Thr790Met and the 3-bromoanilino moiety at the 4-position of quinazoline inhibitors.<a onclick="showRef(event, 'ref12 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref17">(12, 17)</a> We reasoned that the binding of ligands such as erlotinib to EGFR-Thr790Met would not only be hampered by this steric hindrance but also due to the loss of the water-mediated hydrogen bond to the side chain hydroxyl of the Thr790 of EGFR-WT, an interaction which is not possible with the side chain of the mutated Met790. However, we were puzzled by the fact that although EGFR-Thr790Met is a drug resistant mutation with fatal outcome in affected patients, reversible quinazolines such as Erlotinib and Gefitinib lose potency by only 2−3 orders of magnitude while irreversible 4-anilinoquinazolines still inhibit EGFR-Thr790Met in the subnanomolar range in biochemical assays.<a onclick="showRef(event, 'ref12 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref17">(12, 17)</a> We hypothesized that if the N3 of the quinazoline does play an essential role in binding to EGFR, via the formation of a hydrogen bond, the gatekeeper Thr to Met mutation should have resulted in a much more dramatic loss of activity. Therefore, we investigated the requirement of a nitrogen atom at the 3-position of the ten-membered ring system (e.g., <b>2a</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) for potent inhibition of EGFR and proposed, contrary to the SAR reported by Rewcastle et al.<i>,</i><a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> that 6,7-substituted quinolines (<b>2b</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) would also be effective inhibitors of EGFR. Excluding the direct steric effect of the Met790 side chain on binding, we believed that the binding mode of the quinoline inhibitor (<b>2b</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) to EGFR-WT would be comparable to that of an analogous quinazoline-based inhibitor bound to drug resistant EGFR-Thr790Met because hydrogen bonding with a Thr790 is not possible in either situation. However, taking these direct steric effects into consideration, the potency of the 4-anilinoquinoline inhibitors against EGFR-WT would be expected to be better than the potency of the more traditional quinazoline-based inhibitors like Erlotinib against EGFR-Thr790Met.</div><div class="NLM_p">Interestingly, at the time we were synthesizing a series of 4-anilinoquinolines to test our hypotheses, the structure factors of the EGFR−Erlotinib complex were made available to the public (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> This allowed us to calculate the corresponding electron density maps (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), and we were surprised to find that there was no electron density supporting the existence of a water molecule mediating the binding of N3 of the quinazoline core to the side chain of Thr790, further stimulating our design of quinoline-based type I kinase inhibitors. To explore the SAR, based on our prediction that the N3 of the quinazoline core should not play a central role in binding to EGFR, we synthesized different quinoline and quinazoline inhibitors and screened these against EGFR and its mutant variants (Leu858Arg and Leu858Arg-Thr790Met) in biochemical (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) and cellular assays (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Focused Library of Designed 4-Anilinoquinoline-Based Inhibitors and their 4-Anilinoquinazoline Counterparts<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0007.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top"><td><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0008.gif" alt="" id="fx2" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">The structures of reversible and irreversible 4-anilinoquinoline- and 4-anilinoquinazoline-based inhibitors are shown. On the basis of their binding mode to the kinase domain of EGFR, the individual inhibitors are classified as follows: irreversible <b>3a</b>; reversible <b>3c</b>, <b>3e</b>, and <b>4a</b>,<b>b</b>, quinolines and irreversible <b>3b</b>; reversible <b>3d</b>, <b>3f</b>, Erlotinib and <b>4c</b>, quinazolines. IC<sub>50</sub> values were measured with an activity based phosphorylation assay (HTRF). Both reversible and irreversible quinolines give IC<sub>50</sub> values more or less comparable to their quinazoline counterparts, demonstrating that the 4-anilinoquinoline-core is indeed suitable for targeting EGFR.</p></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Quinoline and quinazoline inhibitors (<b>3a</b>−<b>f</b> and <b>4a−c</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) were designed to perform comparative SAR studies. 4-Anilinoquinolines <b>3a</b>,<b>c</b>,<b>e</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) and 4-anilinoquinazolines <b>3b</b>,<b>d</b>,<b>f</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) were synthesized starting from the intermediates <b>8a</b> and <b>8b</b>, respectively. These intermediates were synthesized by two different routes as described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Synthesis of <b>8a</b> was achieved by regioselective nitration of 4-hydroxyquinoline <b>5</b> at the 6-position, using nitric acid in sulfuric acid at −15 °C, to afford 6-nitro-4-hydroxyquinoline <b>6</b>. Chlorination of <b>6</b> resulted in the 4-chloro-6-nitroquinoline <b>7</b>, which was heated at reflux with 4-bromoaniline and catalytic amounts of hydrochloric acid in isopropyl alcohol to give <b>8a</b>. The intermediate <b>8b</b>, which was required for the synthesis of quinazolines <b>3b</b>, <b>3d</b>, and <b>3f</b>, was obtained by starting from 2-amino-5-nitrobenzonitrile <b>9</b>, which on treatment with dimethylformamide−dimethylacetal (DMF−DMA) in toluene produced the <i>N</i>,<i>N</i>-dimethylformamidine derivative <b>10</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Compound <b>10</b> was heated at reflux with 3-bromoaniline in acetic acid to give intermediate <b>8b</b>. Finally, the nitro groups of <b>8a</b>,<b>b</b> were reduced using iron in acetic acid, followed by acylation of the resulting amines <b>11a</b>,<b>b</b> with the corresponding acid chlorides to obtain the 4-anilinoquinoline and quinazoline derivatives <b>3a</b>−<b>e</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). 4-(Dimethylamino)butanoyl chloride <b>13</b> required for <b>3e</b> was synthesized in situ from the corresponding acid <b>12</b> using oxalyl chloride and catalytic amounts of DMF. Compound <b>3f</b> was synthesized from <b>11b</b> and 4-(dimethylamino)butyric acid hydrochloride <b>12</b>, using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI·HCl) as a coupling reagent. The 4-hydroxyquinoline and quinazoline derivatives <b>14a</b>−<b>c</b>, required for the synthesis of the 6,7-disubstituted 4-anilinoquinolines and quinazolines <b>4a</b>−<b>c</b>, were prepared by using procedures described in the literature.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17-19)</a> The 4-hydroxyquinoline and quinazoline derivatives <b>14a</b>−<b>c</b> were subsequently treated with phosphorus oxychloride and catalytic <i>N</i>,<i>N</i>′-dimethylformamide to afford <b>15a</b>−<b>c</b>. Finally, <b>4a</b>−<b>c</b> were obtained from <b>15a</b>−<b>c</b> by the treatment with commercially available 3-ethynylphenylamine and a catalytic amount of concentrated hydrochloric acid in isopropyl alcohol (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0009.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinoline and Quinazoline Derivatives I<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HNO<sub>3</sub>/H<sub>2</sub>SO<sub>4</sub>, −15 to 0 °C; (b) POCl<sub>3</sub>, cat. DMF, reflux; (c) 3-bromoaniline, cat. conc HCl, isopropyl alcohol, reflux; (d) DMF acetal, reflux; (e) 3-bromoaniline, HOAc, reflux; (f) Fe, HOAc, aq EtOH, reflux; (g) RCOCl, DIEA, THF, 0 °C to rt; (h) oxalyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, cat. DMF, reflux, 30 min. Compound <b>3f</b> was synthesized from <b>11b</b> and 4-(dimethylamino)butyric acid hydrochloride <b>12</b>, EDCI.HCl, triethylamine, DMF, 0 °C to rt, overnight.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0010.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Quinoline and Quinazoline Derivatives II<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) POCl<sub>3</sub>, cat. DMF, reflux; (b) 3-ethynylphenylamine, cat. conc HCl, isopropyl alcohol, reflux.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Biochemical Screening</h3><div class="NLM_p">To test the above-mentioned hypotheses regarding inhibition of EGFR by 4-anilinoquinolines, enzyme activity assays were performed for EGFR wild type and the two clinically relevant mutant variants EGFR-Leu858Arg (inhibitor-sensitizing mutation) and EGFR-Leu858Arg-Thr790Met (drug resistant mutation), respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Although potencies of the inhibitors varied between the tested mutant kinases, the measured IC<sub>50</sub> values showed the expected trends for reversible and irreversible inhibitors. We observed that all reversible and irreversible 4-anilinoquinoline-based inhibitors showed low to subnanomolar IC<sub>50</sub> values on EGFR wild type and EGFR-Leu858Arg. When compared to their reversible quinazoline counterparts, quinolines <b>3c</b>, <b>4a</b> (corresponding quinoline to the marketed drug Erlotinib), and <b>4b</b> showed decreased potency by 1−2 orders of magnitude. Interestingly, this trend was not observed for <b>3e</b>, a quinoline containing an <i>N</i>,<i>N</i>-dimethylamino-butynoyl group in the 6-position of the quinoline core. The design of this compound and its quinazoline counterpart <b>3f</b> was stimulated by a charged interaction we previously observed for irreversible quinazoline-based EGFR inhibitors, decorated with an (<i>E</i>)-4-(dimethylamino)but-2-enamide electrophile in the quinoline 6-position, bound to mutant variants of the tyrosine kinase cSrc (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QQ7">2QQ7</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QLQ">2QLQ</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In these structures, the <i>N</i>,<i>N</i>-dimethylamino group is within hydrogen bonding distance to the side chain of Asp348. cSrc and EGFR share high identity in sequence (37% overall) and structure and the ATP binding sites are highly conserved (70%). Structural modeling of the identified binding mode in cSrc to the kinase domain of EGFR supported that this interaction of the protonated tertiary amine of the inhibitor with the side chain of Asp348 in cSrc could be conserved in EGFR via the isostructural Asp800 and should result in increased potency when introduced into reversible inhibitors (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). While all reversible quinolines showed a decreased affinity in drug resistant EGFR-Leu858Arg-Thr790Met, the irreversible inhibitors <b>3a</b> and <b>3b</b> retained potency in the subnanomolar range. These trends are well documented for 4-aminoquinazolines,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> but to the best of our knowledge have not been reported for 4-aminoquinolines and can be directly linked to the enlarged amino acid side chain at the gatekeeper position.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Proposed binding mode of 4-anilinoquinolines to EGFR. (a) <b>3e</b> is modeled into the ATP-binding site of EGFR based on the crystal structure of Erlotinib in complex with EGFR (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>) and an irreversible quinazoline in complex with cSrc (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QLQ">2QLQ</a>). The ring nitrogen of the quinoline forms a hydrogen bond (red dotted line) with the backbone of the hinge region (pink). The protonated tertiary amine of <b>3e</b> is within hydrogen bonding distance to the side chain of Asp800. This additional interaction is not observed for different substituted quinolines and helps to explain the gain in affinity for <b>3e</b>. (b) The irreversible 4-anilinoquinoline <b>3a</b> is modeled into the ATP-binding site of EGFR based on the crystal structure of its quinazoline counterpart to EGFR (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J5F">2J5F</a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The electrophile of the inhibitor forms a covalent bond to the side chain of Cys797.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Profiling the Cellular Activity of Quinolines</h3><div class="NLM_p">To determine the activity of the 4-anilinoquinolines in vitro, cellular-based screening of all the synthesized quinolines as well as on the structurally corresponding quinazolines and Erlotinib was performed in EGFR-dependent Ba/F3 cell lines. These cell lines express a series of clinically relevant EGFR-mutations, either with or without the Thr790Met gatekeeper mutation in EGFR (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> We found the quinolines to be active in all EGFR mutant Ba/F3 cells that did not express the gatekeeper mutation, with GI<sub>50</sub> values within the range of their structurally corresponding quinazolines. We next tested the ability of quinoline <b>3a</b> and <b>3e</b> to inhibit cell growth of patient derived NSCLC cell lines expressing mutant EGFR. Recapitulating our previous results, both quinolines robustly decreased viability of EGFR-mutated PC9 cells at submicromolar concentrations in the range of the activity of the quinazoline Erlotinib (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b). As expected, the irreversible quinoline <b>3a</b> is also active in cells (H1975) expressing the gatekeeper mutation Thr790Met in EGFR (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b). To assess the on-target activity of the quinolines, we determined the phosphorylation status of EGFR in PC9 cells after treatment with either <b>3a</b> or <b>3e</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>c), and this showed inhibition of EGFR autophosphorylation in a dose dependent manner.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. 4-Anilinoquinolines inhibit growth of EGFR-dependent cancer cells. (a) GI<sub>50</sub> values for 4-anilinoquinoline- and 4-anilinoquinazoline-based EGFR inhibitors screened against Ba/F3 cell lines expressing different EGFR mutants with or without the secondary Thr790Met gatekeeper mutation (TM). The range of compound activity is color-coded. (b) The EGFR mutant NSCLC cell line PC9 was treated with increasing concentrations of <b>3a</b> (irreversible) and <b>3e</b> (reversible), and cell viability was determined using measurement of ATP content. The error bars represent the standard deviation for three replicates. (c) The NSCLC cell line H1975 expressing the Thr790Met EGFR gatekeeper mutation was treated with increasing concentrations of <b>3a</b> and <b>3e</b>, and cell viability was determined using measurement of ATP content. The error bars represent the standard deviation for three replicates. (d) Inhibition of the activation status of EGFR was determined by immunoblotting after treatment of PC9 cells with increasing concentrations of <b>3a</b> and <b>3e</b> (from left to right: control, 0.1, 0.3, 1, 3, 10 μM); actin was detected as loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Kinase Profiling</h3><div class="NLM_p">To compare the kinase inhibitor selectivity of our newly developed 4-anilinoquinolines with their quinazoline counterparts, kinase profiling was performed for <b>3e</b> and <b>3f</b> against a panel of 95 different protein kinases measuring the inhibition of kinase activity at a concentration of 10 μM (National Centre for Protein Kinase Profiling, University of Dundee, UK) (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Both compounds showed the highest inhibitory effect, with equal potency, on the receptor tyrosine kinase HER4, the tyrosine kinases Lck and Yes1, as well as on the serine/threonine kinase RIPK2. Of particular interest was the finding that all these kinases possess a threonine at the gatekeeper position, suggesting that the N3 of the quinazoline inhibitor <b>3f</b> is unlikely to play a significant role in binding to these kinases. For the kinases that are weakly or moderately inhibited, a preference for one inhibitor over the other was observed. For example, the potency of the quinoline <b>3e</b> was higher than for the quinazoline counterpart <b>3f</b>, against EPBH-3, cSrc (Thr), and MINK1 (Met), while the quinazoline <b>3f</b> exhibited higher activity against PHK (Phe), PIM1 (Leu), and SmMLCK (Leu) kinases.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinase selectivity profile of <b>3e</b> and <b>3f</b>. Kinase profiling was performed for <b>3e</b> and <b>3f</b> against a panel of 95 different protein kinases at a concentration of 10 μM (National Centre for Protein Kinase Profiling, University of Dundee, UK). The screening was carried out using a radioactive (<sup>33</sup>P-ATP) filter-binding assay. The scores represent the % activity remaining relative to the 100% DMSO controls. The inhibition is color coded from red (strong inhibition, low score) to green (weak inhibition, high score). Both quinazoline- and quinoline-based inhibitors show preference for kinases with a small amino acid at the gatekeeper position (Thr).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The improved understanding of kinase biology in disease states and a more precise description of inhibitor scaffold interactions with their target proteins has resulted in the design and development of a steadily increasing arsenal of potent and selective kinase inhibitors for targeted therapies and chemical biology research. Among the classical kinase inhibitors, compounds derived from ten-membered nitrogen-containing bicyclic scaffolds such as quinazolines represent a privileged chemotype that forms hydrogen bonds to the hinge region of the kinase domain and mimics the adenine ring of ATP. Several potent, quinoline-based type II inhibitors, which not only bind to the hinge region of the ATP pocket but also extend past the gatekeeper residue into an adjacent allosteric site to stabilize enzymatically inactive DFG-out kinase conformations, have been reported for p38α<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and VEGFR,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> respectively. However, quinoline-based type I inhibitors have been presumed to be suboptimal and are therefore clearly underrepresented in kinase inhibitor literature. In the present study, we demonstrate that reversible as well as irreversible inhibitors based on the 4-anilinoquinoline scaffold can be as potent as their quinazoline counterparts. In light of this observation, it is thus felt that they may serve as valuable starting points for further compound design.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> General</h4><div class="NLM_p">Unless otherwise noted, all reagents and solvents were purchased from Acros, Fluka, Sigma Aldrich, or Merck and used without further purification. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance DRX 400 spectrometer at 400 and 125 MHz or 100 MHz, respectively. Chemical shifts (δ) are given in ppm downfield from tetramethylsilane as an internal standard. Analytical TLC was carried out on Merck 60 F245 aluminum-backed silica gel plates. Compounds were purified by column chromatography using Baker silica gel (40−70 μm particle size). Preparative HPLC was conducted on a Varian HPLC system (Pro Star 215) with a VP 250/21 Nucleosil C18 PPN column from Macherey-Nagel and monitored by UV at 254 nm. High resolution electrospray ionization mass spectra (ESI-FTMS) were recorded on a Thermo LTQ Orbitrap (high resolution mass spectrometer from Thermo Electron) coupled to an “Accela” HPLC System supplied with a “Hypersil GOLD” column (Thermo Electron).</div><div class="NLM_p last">All tested compounds possessed a purity of >95% as determined by HPLC coupled with mass spectroscopy (HPLC-ESI-MS). HPLC-ESI-MS analyses were performed on an HPLC system from Agilent (1200 series) with an Eclipse XDB-C18, 5 μm (column dimensions: 150 mm × 4.60 mm) column from Agilent and UV detection at 254 nm coupled to a Thermo Finnigan LCQ Advantage Max ESI-spectrometer. H<sub>2</sub>O with 0.1% formic acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B) was used at a flow of 1 mL/min as a solvent system for HPLC-ESI-MS along with the gradient: 0 min, 90% solvent A/10% solvent B; 1 min, 90% solvent A/10% solvent B; 10 min, 0% solvent A/100% solvent B; 12 min, 0% solvent A/100% solvent B; 15 min, 90% solvent A/10% solvent B.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> <i>N</i>-(4-(3-Bromophenylamino)quinolin-6-yl)acrylamide (<b>3a</b>)</h4><div class="NLM_p last">Compound <b>3a</b> was prepared according to the literature procedure<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> using <i>N</i><sup>4</sup>-(3-bromophenyl)quinoline-4,6-diamine <b>11a</b> (0.32 g, 1.02 mmol), 250 mM solution of acryloyl chloride (4.07 mL, 1.02 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (266 μL, 1.5 mmol), and THF (103 mL) to produce the 62.0 mg (16.5%) of white solid after the preparative HPLC purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.85−10.42 (m, 2H), 9.07 (s, 1H), 8.50 (d, <i>J</i> = 6.8 Hz, 1H), 8.11−7.92 (m, 2H), 7.70 (s, 1H), 7.61−7.55 (m, 1H), 7.62−7.47 (m, 2H), 6.92 (d, <i>J</i> = 6.8 Hz, 1H), 6.53 (dd, <i>J</i> = 10.1, 17.0 Hz, 1H), 6.35 (dd, <i>J</i> = 1.9, 17.0 Hz, 1H), 5.86 (dd, <i>J</i> = 1.9, 10.1 Hz, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 164.47, 155.02, 142.95, 140.37, 138.52, 136.04, 132.59, 132.17, 130.59, 128.86, 128.62, 128.49, 124.82, 123.11, 122.36, 119.02, 112.59, 101.58. HRMS (ESI-MS) calcd 368.0393 for C<sub>18</sub>H<sub>15</sub>BrN<sub>3</sub>O [M + H<sup>+</sup>], found 368.0397. LC-MS <i>t</i><sub>R</sub> = 6.7 min, purity ≥ 99%.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> <i>N</i>-(4-(3-Bromophenylamino)quinolin-6-yl)propionamide (<b>3c</b>)</h4><div class="NLM_p last">A 10 mL round-bottom flask was flushed with argon and charged with <b>11a</b> (0.1 g, 0.32 mmol), DIEPA (0.14 mL, 0.67 mmol), and dry THF and cooled down to 0 °C. Then a 100 mM solution of propionylchloride (0.28 mL, 0.32 mmol) was added dropwise to the reaction mixture. The reaction was stirred for an hour from 0 °C to room temperature. The progress of reaction was monitored by TLC, and upon completion the reaction mixture was basified with 10% aq NaHCO<sub>3</sub>. The water phase was extracted with ethyl acetate (3 × 10 mL), and the combined organic layers were washed with water and dried over Na<sub>2</sub>SO<sub>4</sub>. The volatiles were removed in vacuo affording a yellow solid, which was further purified by column chromatography using DCM/MeOH (8:1) as an eluent to produce 42 mg (35%) of the title compound. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, br, 1H), 9.02 (s, br, 1H), 8.62 (d, <i>J</i> = 2 Hz, 1H), 8.46 (d, <i>J</i> = 5.1 Hz, 1H), 7.86 (d, <i>J</i> = 9.0 Hz, 1H), 7.76 (dd, <i>J</i> = 2, 9.0 Hz, 1H), 7.50 (s, 1H), 7.38−7.28 (m, 2H), 7.22 (dd, <i>J</i> = 3.4, 5.4 Hz, 1H), 7.08 (d, <i>J</i> = 5.1 Hz, 1H), 2.40 (q, <i>J</i> = 7.5 Hz, 2H), 1.13 (t, <i>J</i> = 7.5, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.99, 149.76, 147.27, 146.43, 144.44, 137.01, 132.02, 130.24, 125.69, 124.50, 123.54, 122.95, 121.89, 119.85, 111.26, 105.15, 30.34, 10.53. HRMS (ESI-MS) calcd 370.0550 for C<sub>18</sub>H<sub>17</sub>BrN<sub>3</sub>O [M + H<sup>+</sup>], found: 370.0553. <i>t</i><sub>R</sub> = 6.5 min, purity = 98%.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> <i>N</i>-(4-(3-Bromophenylamino)quinolin-6-yl)-4-(dimethylamino)butanamide (<b>3e</b>)</h4><div class="NLM_p last">(<i>E</i>)-4-(Dimethylamino)but-2-enoic acid hydrochloride (80 mg, 0.32 mmol) was stirred in 4 mL of THF under argon for 5 min. The solution was then cooled in an ice bath and DMF (50 μL) was added, followed by dropwise addition of oxalyl chloride (85 μL, 1.0 mmol). The reaction was stirred at room temperature for 2 h until a deep-orange color was observed. Then the reaction mixture was cooled in an ice bath for 10 min, and a solution of <b>11a</b> (0.1 g, 0.32 mmol) in 1-methyl-2-pyrrolidinone was added dropwise. Stirring was continued for the next 30 min in an ice bath, followed by stirring at room temperature for 2 h. Upon completion of the reaction, a saturated aqueous solution of NaHCO<sub>3</sub> was added to the reaction mixture until it became alkaline (pH 8−9). The resulting solid was then filtered off and purified by column chromatography (5−10% MeOH in DCM) to obtain a yellow solid product <b>3e</b> (56 mg, 41%); mp 186−187 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.91 (s, 1H), 8.58 (s, 1H), 8.44 (d, <i>J</i> = 4.9 Hz, 1H), 7.83 (d, <i>J</i> = 9.0 Hz, 1H), 7.73 (dd, <i>J</i> = 2.2, 9.1 Hz, 1H), 7.47 (s, 1H), 7.33−7.26 (m, 3H), 7.18 (d, <i>J</i> = 6.9 Hz, 1H), 7.06 (d, <i>J</i> = 4.9 Hz, 1H), 2.38 (t, <i>J</i> = 7.3 Hz, 2H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 2.13 (s, 6H), 1.74 (qn, <i>J</i> = 7.3 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.30, 147.16, 146.63, 144.35, 136.91, 132.04, 130.41, 125.73, 124.42, 123.56, 122.95, 121.85, 119.88, 111.18, 105.13, 59.27, 45.90, 34.98, 23.78. HRMS (ESI-MS) calcd 427.1128 for C<sub>21</sub>H<sub>24</sub>BrN<sub>4</sub>O [M + H<sup>+</sup>], found 427.1126. <i>t</i><sub>R</sub> = 5.19 min, purity = 99.0%.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>N</i>-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinolin-4-amine (<b>4a</b>)</h4><div class="NLM_p last">3-Ethynylaniline 37.6 mg (0.32 mmol) and catalytic amount of 2N HCl (50 μL) was added to the solution of 4-chloro-6,7-bis(2-methoxyethoxy)quinoline (0.1 g, 0.32 mmol) in isopropyl alcohol, and reaction mixture was heated under reflux for 2 h. The reaction mixture was cooled to room temperature and basified with 10% aq sodium bicarbonate, followed by extraction with CHCl<sub>3</sub>/MeOH (4:1). The combined organic layers were washed with water and dried over Na<sub>2</sub>SO<sub>4</sub>. The volatiles were removed in vacuo and resulting material was purified with column chromatography using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:1 to 100:7) as an eluent to afford a 42 mg (33%) of yellow solid . <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 9.52 (s, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.60 (s, 1H), 7.56−7.42 (m, 5H), 6.76 (d, <i>J</i> = 6.8 Hz, 1H), 4.31 (dd, <i>J</i> = 3.7, 5.3 Hz, 2H), 4.26−4.21 (m, 2H), 3.83−3.75 (m, 4H), 3.50 (s, 1H), 3.43 (s, 3H), 3.41 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD3CN) δ 154.76, 153.21, 149.54, 139.92, 138.35, 136.04, 130.62, 130.56, 128.13, 125.73, 123.91, 112.40, 102.59, 101.28, 99.99, 82.63, 79.51, 70.57, 70.38, 69.15, 69.02, 58.64, 58.62. HRMS (ESI-MS) calcd 393.1809 for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub> [M + H<sup>+</sup>], found 393.1812. <i>t</i><sub>R</sub> = 6.56 min, purity = 98.7%.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> <i>N</i>-(3-Ethynylphenyl)-6,7-dimethoxyquinolin-4-amine (<b>4b</b>)</h4><div class="NLM_p last">Compound <b>4b</b> was synthesized in the similar way as described for <b>4a</b> using 4-chloro-6,7-dimethoxyquinoline (0.2 g, 0.9 mmol), 3-ethynylaniline (0.1 g, 0.9 mmol), and catalytic amount of 2N HCl (50 μL). The crude was purified over silica gel using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:1 to 100:5) as an eluent affording 0.24 g (86%) of <b>4b</b>; mp 253−255 °C. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.25 (d, <i>J</i> = 7.0 Hz, 1H), 7.88 (s, 1H), 7.60−7.48 (m, 4H), 7.30 (s, 1H), 6.86 (d, <i>J</i> = 7.0 Hz 1H), 4.10−4.00 (m, 6H), 3.68 (s, 1H). <sup>13</sup>C NMR (100 MHz, Me<sub>3</sub>OD) δ 156.29, 154.32, 150.96, 139.61, 138.18, 136.05, 131.02, 130.41, 128.77, 126.02, 124.74, 112.39, 101.52, 99.66, 99.58, 82.19, 79.33, 56.08, 56.06. HRMS (ESI-MS) calcd 305.1285 for C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> [M + H<sup>+</sup>], found 305.1284. <i>t</i><sub>R</sub> = 6.27 min, purity = 98.2%.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>N</i>-(3-Ethynylphenyl)-6,7-dimethoxyquinazolin-4-amine (<b>4c</b>)</h4><div class="NLM_p last">Compound <b>4c</b> was synthesized by following the procedure described for <b>4a</b> using, 4,4-chloro-6,7-dimethoxyquinazoline (0.2 g, 0.9 mmol), 3-ethynylaniline (0.1 g, 0.9 mmol), and catalytic amount of 2N HCl (50 μL). The crude was purified over silica gel using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:1 to 100:5) as an eluent affording 0.25 g (92%) of <b>4c</b>; mp 290−292 °C. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.73 (s, 1H), 7.99 (s, 1H), 7.88 (s, 1H), 7.74 (d, <i>J</i> = 7.8 Hz, 1H), 7.52−7.37 (m, 2H), 7.26 (s, 1H), 4.07 (s, 3H), 4.08 (s, 3H), 3.62 (s, 1H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 159.06, 158.05, 151.85, 148.45, 137.34, 135.83, 130.15, 129.16, 127.82, 124.92, 123.48, 107.80, 102.74, 99.34, 82.59, 78.60, 56.34, 56.22. HRMS (ESI-MS) calcd 306.1237 for C<sub>19</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub> [M + H<sup>+</sup>], found 306.1236. <i>t</i><sub>R</sub> = 6.15 min, purity = 97.4%.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-(4-(3-Bromophenylamino)quinazoline-6-yl)acrylamide (<b>3b</b>)</h4><div class="NLM_p last">The compound is prepared according to the literature procedure<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> from <i>N</i><sup>4</sup>-(3-bromophenyl)-4,6-quinazolinediamine (0.3 g, 0.95 mmol), acryloyl chloride (95 μL, 1.14 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (380 mL, 2.29 mmol), and THF (103 mL) to produce 40 mg (11%) of white solid upon purification using preparative HPLC. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.48 (bs, 1H), 9.91 (bs, 1H), 8.82 (d, <i>J</i> = 2.2 Hz, 1H), 8.59 (s, 1H), 8.19 (t, <i>J</i> = 1.9 Hz, 1H), 7.93−7.85 (m, 2H), 7.79 (d, <i>J</i> = 9.0 Hz, 1H), 7.34 (t, <i>J</i> = 8.0 Hz, 1H), 7.31−7.26 (m, 1H), 6.53 (dd, <i>J</i> = 10.1, 17.0 Hz, 1H), 6.35 (dd, <i>J</i> = 1.9, 17.0 Hz, 1H), 5.83 (dd, <i>J</i> = 1.9, 10.1 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.34, 157.28, 153.18, 146.83, 141.14, 136.63, 131.54, 130.33, 128.56, 127.48, 127.24, 125.89, 124.24, 121.20, 120.77, 115.49, 112.24. HRMS (ESI-MS): calcd for C<sub>17</sub>H<sub>14</sub>BrN<sub>4</sub>O [M + H<sup>+</sup>] 369.03455, found 369.03506. t<sub>R</sub> = 7.12 min, purity = 99.4%.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(4-(3-Bromophenylamino)quinazoline-6-yl)propionamide (<b>3d</b>)</h4><div class="NLM_p last">The compound was synthesized from <i>N</i><sup>4</sup>-(3-bromophenyl)-4,6-quinazolinediamine (0.1 g, 0.32 mmol), propionyl chloride (31 μL, 0.47 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (110 μL, 0.67 mmol) in 3.5 mL of THF according to the literature.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> An off-white solid (40 mg, 37%) was produced upon preparative HPLC. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.2 (s, 1H), 9.90 (s, 1H), 8.73 (s, 1H), 8.57 (s, 1H), 8.17 (s, 1H), 7.89−7.81 (m, 2H), 7.77 (d, <i>J</i> = 8.9 Hz, 1H), 7.34 (t, <i>J</i> = 8.0 Hz, 1H), 7.28 (d, <i>J</i> = 8.0 Hz, 1H), 2.41 (q, <i>J</i> = 7.5 Hz, 2H), 1.14 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 172.13, 157.22, 152.86, 146.46, 141.21, 137.05, 130.26, 128.36, 127.16, 125.77, 124.23, 121.09, 120.81, 115.45, 111.62, 29.36, 9.56. HRMS (ESI-MS): calcd for C<sub>17</sub>H<sub>16</sub><sup>79</sup>BrN<sub>4</sub>O [M + H<sup>+</sup>] 371.05020, found 371.05074. <i>t</i><sub>R</sub> = 8.71 min, purity = 98.2%.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-{4-[(3-Bromo-phenyl)amino]-quinazoline-6-yl}-4-(dimethylamino)butanamide (<b>3f</b>)</h4><div class="NLM_p last">4-(Dimethyl amino)-butyric acid hydrochloride (0.1 g, 0.506 mmol) and triethylamine (0.18 mL, 2.02 mmol) were stirred in 3 mL of DMF at 0 °C for 10 min. EDC·HCl (0.130 g, 1.01 mmol) was added, and the reaction mixture was further stirred for 10 min. The <i>N</i><sup>4</sup>-(3-bromophenyl)-4,6-quinazolinediamine (0.1 g, 0.31 mmol) was then added as a solid, and the reaction mixture was stirred at 0 °C for 30 min and then overnight at room temperature. On the next day, 0.5 mL of triethylamine was added, and the reaction mixture was extracted with ethyl acetate, washed with brine, and the organic phase was dried with sodium sulfate. Ethyl acetate was removed to obtain an oily residue which was purified by preparative HPLC to obtain 27 mg (19%) of a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.25 (s, 1H), 9.88 (s, 1H), 8.72 (d, <i>J</i> = 1.9 Hz, 1H), 8.57 (s, 1H), 8.16 (t, <i>J</i> = 1.9 Hz, 1H), 7.89−7.81 (m, 2H), 7.75 (d, <i>J</i> = 8.9 Hz, 1H), 7.34 (t, <i>J</i> = 8.0 Hz, 1H), 7.30−7.26 (m, 1H), 2.42 (t, <i>J</i> = 7.4 Hz, 2H), 2.27 (t, <i>J</i> = 7.1 Hz, 2H), 2.15 (s, 6H), 1.77 (qn, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.36, 157.23, 152.86, 146.48, 141.21, 137.05, 130.25, 128.37, 127.13, 125.77, 124.25, 121.07, 120.83, 115.45, 111.53, 58.46, 45.11(2 × C), 34.02, 22.92. HRMS (ESI-MS): calcd for C<sub>20</sub>H<sub>23</sub>BrN<sub>5</sub>O [M + H<sup>+</sup>] 428.10805, found 428.10792. <i>t</i><sub>R</sub> = 6.18 min, purity = 98.3%.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Kinetics Assay for IC<sub>50</sub> Determination</h3><div class="NLM_p last">IC<sub>50</sub> determinations for wild type and mutants of EGFR were measured with the HTRF KinEASE-TK assay from Cisbio according to the manufacturer’s instructions. A biotinylated poly Glu-Tyr substrate peptide was phosphorylated by EGFR. After completion of the reaction, an antiphosphotyrosine antibody labeled with europium cryptate and streptavidin labeled with the fluorophore XL665 were added. The FRET between europium cryptate and XL665 was measured to quantify the phosphorylation of the substrate peptide. ATP concentrations were set at their respective <i>K</i><sub>m</sub> values (30 μM for the EGFR-WT, 60 μM for EGFR-Leu858Arg, and 30 μM for EGFR-Leu858Arg, Thr790Met), and 50 nM of substrate were used for both wild type and mutant EGFR. Kinase, substrate peptide, and inhibitor were preincubated for 2 h before the reaction was started by addition of ATP. A Tecan Safire<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> plate reader was used to measure the fluorescence of the samples at 620 nm (Eu-labeled antibody) and 665 nm (XL665 labeled streptavidin) 60 μs after excitation at 317 nm. The quotient of both intensities for reactions made with eight different inhibitor concentrations (including no inhibitor) were plotted against inhibitor concentrations and fit to a Hill 4-parameter equation to determine IC<sub>50</sub> values. Each reaction was performed in duplicate, and at least three independent determinations of each IC<sub>50</sub> were made.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Structural Modeling</h3><div class="NLM_p last">The small molecule structures of 4-anilinoquinolines were sketched and minimized in DS ViewerPro (<a href="http://www.accelrys.com" class="extLink">http://www.accelrys.com</a>) and aligned to the kinase domains of the EGFR-erlotinib (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>) and EGFR−<b>3b</b> complexes (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J5F">2J5F</a>) using PyMol (<a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>). In the modeled 4-anilinoquinoline EGFR complexes, the inhibitors adopt binding modes isostructural to erlotinib or <b>3b</b> in EGFR. N1 of the quinoline scaffold forms one key hydrogen bond to the backbone of the hinge region (Met793 in EGFR).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Cell Lines</h3><div class="NLM_p last">NSCLC cells were obtained from ATCC (<a href="http://www.atcc.org" class="extLink">www.atcc.org</a>) and were maintained as described previously.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Ba/F3 cell lines were established as described previously<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and were maintained in RPMI media containing 10% FCS and 1% of penicillin and streptomycin.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Viability Assays</h3><div class="NLM_p last">The assay was set out as described previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In brief, cells were plated into sterile 96-well plates using a Multidrop instrument (<a href="http://www.thermo.com" class="extLink">www.thermo.com</a>) and after 24 h of incubation a dilution series of compounds was added. Viability was determined after 96 h using the Cell Titer-Glo assay (<a href="http://www.promega.com" class="extLink">www.promega.com</a>). Luminescence was measured on a Mithras LB940 plate reader (<a href="http://www.bertholdtech.com" class="extLink">www.bertholdtech.com</a>). Half-maximal inhibitory concentrations were determined using the R package “ic50”.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Immunoblotting</h3><div class="NLM_p last">Immunoblotting was performed using standard procedures as described before.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Briefly, cells were treated for 24 h and concentration of a given compound prior to using whole cell lysates for immunoblotting. The following antibodies were utilized: p-EGFR (Biosource, USA), antirabbit-antibody, antimouse (Millipore, Germany). The enhanced chemiluminescence (ECL) system (Amersham-Pharmacia) was used to develop the blots.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29"><a href="/doi/suppl/10.1021/jm901877j">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Figure and experimental data for compounds <b>7</b>, <b>8a</b>, <b>11a</b>, <b>15a</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901877j/suppl_file/jm901877j_si_001.pdf">jm901877j_si_001.pdf (292.85 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm901877j" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Rauh</span> - <span class="hlFld-Affiliation affiliation">Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2a4e4b44434f4604584b5f426a494d4904475a4d044e4f"><span class="__cf_email__" data-cfemail="94f0f5fafdf1f8bae6f5e1fcd4f7f3f7baf9e4f3baf0f1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vijaykumar G. Pawar</span> - <span class="hlFld-Affiliation affiliation">Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin L. Sos</span> - <span class="hlFld-Affiliation affiliation">Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Gleueler Strasse 50, 50931 Köln, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haridas B. Rode</span> - <span class="hlFld-Affiliation affiliation">Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias Rabiller</span> - <span class="hlFld-Affiliation affiliation">Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefanie Heynck</span> - <span class="hlFld-Affiliation affiliation">Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Gleueler Strasse 50, 50931 Köln, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Willem A. L. van Otterlo</span> - <span class="hlFld-Affiliation affiliation">Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roman K. Thomas</span> - <span class="hlFld-Affiliation affiliation">Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Gleueler Strasse 50, 50931 Köln, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Department I of Internal Medicine and Center of Integrated Oncology Köln—Bonn, University of Köln, 50924 Köln, Germany</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21646" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21646" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Rogier Buijsman and Michael Beck for helpful discussions. The work was supported by the German Federal Ministry for Education and Research through the German National Genome Research Network-Plus (NGFN-Plus) (BMBF grant 01GS08102), all to D.R., and by the Deutsche Krebshilfe (grant 107954), by the Fritz-Thyssen-Stiftung (grant 10.08.2.175) as well as by the German National Genome Research Network-Plus (NGFN-Plus) (BMBF grant 01GS08100), all to R.K.T. W.A.L.vO. thanks the Alexander von Humboldt Foundation for a Georg Forster Research Fellowship for Experienced Researchers and the University of the Witwatersrand for sabbatical leave. Schering Plough, Bayer-Schering Pharma, Merck-Serono, and Bayer CropScience are thanked for financial support.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 26 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhjcYWsBAtjYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1517%2F17460440802579975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=23506106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1409-1425&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinases.+Part+I%3A+exceptions+from+the+traditional+pharmacophore+approach+of+type+I+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span></div><div class="casAuthors">Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Mueller, G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-1425</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Protein kinases are essential enzymes propagating cellular signal transduction processes and consequently have emerged as central targets for drug discovery against a wide range of diseases with a strong historical focus on oncol. disorders.  A large no. of high-resoln. crystal structures of various ATP-competitive inhibitors in complex with their target protein kinases have been detd. and present a wealth of detailed information about binding modes, inhibition mechanisms and assocd. structure-activity relationships of target-bound small mols.  Objective: In this first part of a two-part review, exceptions to the type I binding mode of kinase inhibitors that follow the traditional pharmacophore model are discussed, highlighting unexpected structural features.  Methods: The scope of this review covers published crystal structures of protein kinases in complex with various ligands.  Results: Structural parameters of both inhibitors and kinases contribute to the complexity of designing kinase inhibitors.  The continued study of high-resoln. structures of ligand-enzyme complexes in combination with a more dynamic understanding of accessible conformational states of the target proteins, supported by detailed kinetic studies, will in the long-term help in developing new low-mol. wt. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxVqECguWJbVg90H21EOLACvtfcHk0lhjcYWsBAtjYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D&md5=705fa7e531ceced90ed86d0d2658766e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1517%2F17460440802579975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460440802579975%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinases.%2520Part%2520I%253A%2520exceptions%2520from%2520the%2520traditional%2520pharmacophore%2520approach%2520of%2520type%2520I%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1409%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1427-1449&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinase.+Part+II%3A+the+novel+pharmacophore+approach+of+type+II+and+type+III+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinase.%2520Part%2520II%253A%2520the%2520novel%2520pharmacophore%2520approach%2520of%2520type%2520II%2520and%2520type%2520III%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1427%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 5. Synthesis and structure−activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3487</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00018a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3482-3487&author=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=A.+J.+Bridgesauthor=H.+R.+Zhouauthor=D.+R.+Codyauthor=A.+McMichaelauthor=D.+W.+Fry&title=Tyrosine+kinase+inhibitors.+5.+Synthesis+and+structure%E2%88%92activity+relationships+for+4-%5B%28phenylmethyl%29amino%5D-+and+4-%28phenylamino%29quinazolines+as+potent+adenosine+5%E2%80%B2-triphosphate+binding+site+inhibitors+of+the+tyrosine+kinase+domain+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm00018a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00018a008%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%2BR.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%25205.%2520Synthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520for%25204-%255B%2528phenylmethyl%2529amino%255D-%2520and%25204-%2528phenylamino%2529quinazolines%2520as%2520potent%2520adenosine%25205%25E2%2580%25B2-triphosphate%2520binding%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3482%26epage%3D3487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span> </span><span class="NLM_article-title">4-Anilino-6,7-dialkoxyquinolime-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3244</span><span class="NLM_x">–</span> <span class="NLM_lpage">3256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000206a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3244-3256&author=A.+Wissnerauthor=D.+M.+Bergerauthor=D.+H.+Boschelliauthor=M.+B.+Floydauthor=L.+M.+Greenbergerauthor=B.+C.+Gruberauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=R.+Nilakantanauthor=M.+F.+Reichauthor=R.+Shenauthor=H.+R.+Tsouauthor=E.+Upeslacisauthor=Y.+F.+Wangauthor=B.+Q.+Wuauthor=F.+Yeauthor=N.+Zhang&title=4-Anilino-6%2C7-dialkoxyquinolime-3-carbonitrile+inhibitors+of+epidermal+growth+factor+receptor+kinase+and+their+bioisosteric+relationship+to+the+4-anilino-6%2C7-dialkoxyquinazoline+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm000206a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000206a%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DUpeslacis%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWu%26aufirst%3DB.%2BQ.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DN.%26atitle%3D4-Anilino-6%252C7-dialkoxyquinolime-3-carbonitrile%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520and%2520their%2520bioisosteric%2520relationship%2520to%2520the%25204-anilino-6%252C7-dialkoxyquinazoline%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3244%26epage%3D3256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">The development of HKI-272 and related compounds for the treatment of cancer</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1002%2Fardp.200800009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=18493974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2008&pages=465-477&author=A.+Wissnerauthor=T.+S.+Mansour&title=The+development+of+HKI-272+and+related+compounds+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The development of HKI-272 and related compounds for the treatment of cancer</span></div><div class="casAuthors">Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">465-477</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of HKI-272 and EKB-569 for the treatment of cancer is described.  These compds. function as irreversible inhibitors of some members of the ErbB family of receptor tyrosine kinases.  In particular, they target epidermal growth factor receptor (EGFR, also known as ErbB-1) and human epidermal growth factor receptor-2 (HER2, also known as ErbB-2).  Both, HKI-272 and EKB-569 are 4-anilino-3-cyano quinoline derivs. that contain a 4-(dimethylamino)crotonamide Michael-acceptor group at the 6-position.  These compds. inhibit the function of the target enzymes by forming a covalent interaction with a conserved cysteine residue located in the kinase domains of these proteins.  The potential advantages of using irreversible inhibitors for this purpose are discussed.  We summarize the recent findings concerning some somatic mutations in EGFR and their relevance with respect to the irreversible inhibitors.  In particular, we highlight the findings that these irreversible inhibitors retain activity against tumors that have acquired a resistance to the reversible binding inhibitors gefitinib and erlotinib.  The promising interim clin. trial results for HKI-272 and EKB-569 in treating colon, lung, and breast cancers are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSokM42ZhprVg90H21EOLACvtfcHk0liVh74t0MB9RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E&md5=2e46d99ca74e297e6a7e860634bf096d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fardp.200800009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200800009%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DThe%2520development%2520of%2520HKI-272%2520and%2520related%2520compounds%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DArch.%2520Pharm.%26date%3D2008%26volume%3D341%26spage%3D465%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Å resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0liVh74t0MB9RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterbein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, G.</span><span> </span><span class="NLM_article-title"><i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6465</span><span class="NLM_x">–</span> <span class="NLM_lpage">6488</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060434q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6465-6488&author=L.+F.+Hennequinauthor=J.+Allenauthor=J.+Breedauthor=J.+Curwenauthor=M.+Fennellauthor=T.+P.+Greenauthor=C.+Lambert-van+der+Bremptauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Olivierauthor=L.+Otterbeinauthor=P.+A.+Pleauthor=N.+Warinauthor=G.+Costello&title=N-%285-Chloro-1%2C3-benzodioxol-4-yl%29-7-%5B2-%284-methylpiperazin-1-yl%29ethoxy%5D-5-+%28tetrahydro-2H-pyran-4-yloxy%29quinazolin-4-amine%2C+a+novel%2C+highly+selective%2C+orally+available%2C+dual-specific+c-Src%2FAbl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm060434q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060434q%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DOtterbein%26aufirst%3DL.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DWarin%26aufirst%3DN.%26aulast%3DCostello%26aufirst%3DG.%26atitle%3DN-%25285-Chloro-1%252C3-benzodioxol-4-yl%2529-7-%255B2-%25284-methylpiperazin-1-yl%2529ethoxy%255D-5-%2520%2528tetrahydro-2H-pyran-4-yloxy%2529quinazolin-4-amine%252C%2520a%2520novel%252C%2520highly%2520selective%252C%2520orally%2520available%252C%2520dual-specific%2520c-Src%252FAbl%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6465%26epage%3D6488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Rachid, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahimi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jean-Claude, B. J.</span><span> </span><span class="NLM_article-title">Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure−activity relationship</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2605</span><span class="NLM_x">–</span> <span class="NLM_lpage">2608</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070144p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2605-2608&author=Z.+Rachidauthor=F.+Brahimiauthor=Q.+Qiuauthor=C.+Williamsauthor=J.+M.+Hartleyauthor=J.+A.+Hartleyauthor=B.+J.+Jean-Claude&title=Novel+nitrogen+mustard-armed+combi-molecules+for+the+selective+targeting+of+epidermal+growth+factor+receptor+overexperessing+solid+tumors%3A+Discovery+of+an+unusual+structure%E2%88%92activity+relationship"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm070144p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070144p%26sid%3Dliteratum%253Aachs%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DBrahimi%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DHartley%26aufirst%3DJ.%2BM.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DNovel%2520nitrogen%2520mustard-armed%2520combi-molecules%2520for%2520the%2520selective%2520targeting%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520overexperessing%2520solid%2520tumors%253A%2520Discovery%2520of%2520an%2520unusual%2520structure%25E2%2588%2592activity%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2605%26epage%3D2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingalls, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nittoli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loganzo, F.</span><span> </span><span class="NLM_article-title">Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3635</span><span class="NLM_x">–</span> <span class="NLM_lpage">3648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=3635-3648&author=A.+Wissnerauthor=H.+L.+Fraserauthor=C.+L.+Ingallsauthor=R.+G.+Dushinauthor=M.+B.+Floydauthor=K.+Cheungauthor=T.+Nittoliauthor=M.+R.+Raviauthor=X.+Z.+Tanauthor=F.+Loganzo&title=Dual+irreversible+kinase+inhibitors%3A+quinazoline-based+inhibitors+incorporating+two+independent+reactive+centers+with+each+targeting+different+cysteine+residues+in+the+kinase+domains+of+EGFR+and+VEGFR-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DFraser%26aufirst%3DH.%2BL.%26aulast%3DIngalls%26aufirst%3DC.%2BL.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DNittoli%26aufirst%3DT.%26aulast%3DRavi%26aufirst%3DM.%2BR.%26aulast%3DTan%26aufirst%3DX.%2BZ.%26aulast%3DLoganzo%26aufirst%3DF.%26atitle%3DDual%2520irreversible%2520kinase%2520inhibitors%253A%2520quinazoline-based%2520inhibitors%2520incorporating%2520two%2520independent%2520reactive%2520centers%2520with%2520each%2520targeting%2520different%2520cysteine%2520residues%2520in%2520the%2520kinase%2520domains%2520of%2520EGFR%2520and%2520VEGFR-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D3635%26epage%3D3648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Michalczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3488</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1016%2Fj.bmc.2008.02.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=18316192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3482-3488&author=A.+Michalczykauthor=S.+Kl%C3%BCterauthor=H.+B.+Rodeauthor=J.+R.+Simardauthor=C.+Gr%C3%BCtterauthor=M.+Rabillerauthor=D.+Rauh&title=Structural+insights+into+how+irreversible+inhibitors+can+overcome+drug+resistance+in+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span></div><div class="casAuthors">Michalczyk, Anja; Klueter, Sabine; Rode, Haridas B.; Simard, Jeffrey R.; Gruetter, Christian; Rabiller, Matthias; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3482-3488</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Resistance to kinase-targeted cancer drugs has recently been linked to a single point mutation in the ATP binding site of the kinase.  In EGFR, the crucial Thr790 gatekeeper residue is mutated to a Met and prevents reversible ATP competitive inhibitors from binding.  Irreversible 4-(phenylamino)quinazolines have been shown to overcome this drug resistance and are currently in clin. trials.  In order to obtain a detailed structural understanding of how irreversible inhibitors overcome drug resistance, the authors used Src kinase as a model system for drug resistant EGFR-T790M.  The authors report the first crystal structure of a drug resistant kinase in complex with an irreversible inhibitor.  This 4-(phenylamino)quinazoline inhibits wild type and drug resistant EGFR in vitro at low nM concns.  The cocrystal structure of drug resistant cSrc-T338M kinase domain provides the structural basis of this activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp52JtORqsX7Vg90H21EOLACvtfcHk0lijkLPYG2iGyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gruro%253D&md5=b9fc704067e495279bad4913e9c703ab</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.053%26sid%3Dliteratum%253Aachs%26aulast%3DMichalczyk%26aufirst%3DA.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructural%2520insights%2520into%2520how%2520irreversible%2520inhibitors%2520can%2520overcome%2520drug%2520resistance%2520in%2520EGFR%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D3482%26epage%3D3488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">11011</span><span class="NLM_x">–</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1073%2Fpnas.0504952102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=16046538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnvVWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span></div><div class="casAuthors">Carter, Todd A.; Wodicka, Lisa M.; Shah, Neil P.; Velasco, Anne Marie; Fabian, Miles A.; Treiber, Daniel K.; Milanov, Zdravko V.; Atteridge, Corey E.; Biggs, William H., III; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Mehta, Shamal A.; Patel, Hitesh K.; Pao, William; Sawyers, Charles L.; Varmus, Harold; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11011-11016</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it is important to address the emergence of drug resistance in treated patients.  Mutant forms of BCR-ABL, KIT, and the EGF receptor (EGFR) have been found that confer resistance to the drugs imatinib, gefitinib, and erlotinib.  The mutations weaken or prevent drug binding, and interestingly, one of the most common sites of mutation in all three kinases is a highly conserved "gatekeeper" threonine residue near the kinase active site.  We have identified existing clin. compds. that bind and inhibit drug-resistant mutant variants of ABL, KIT, and EGFR.  We found that the Aurora kinase inhibitor VX-680 and the p38 inhibitor BIRB-796 inhibit the imatinib- and BMS-354825-resistant ABL(T315I) kinase.  The KIT/FLT3 inhibitor SU-11248 potently inhibits the imatinib-resistant KIT(V559D/T670I) kinase, consistent with the clin. efficacy of SU-11248 against imatinib-resistant gastrointestinal tumors, and the EGFR inhibitors EKB-569 and Cl-1033, but not GW-572016 and ZD-6474, potently inhibit the gefitinib- and erlotinib-resistant EGFR(L858R/T790M) kinase.  EKB-569 and Cl-1033 are already in clin. trials, and our results suggest that they should be considered for testing in the treatment of gefitinib/erlotinib-resistant non-small cell lung cancer.  The results highlight the strategy of screening existing clin. compds. against newly identified drug-resistant mutant variants to find compds. that may serve as starting points for the development of next-generation drugs, or that could be used directly to treat patients that have acquired resistance to first-generation targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdgFgcC03tybVg90H21EOLACvtfcHk0lijkLPYG2iGyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnvVWjurg%253D&md5=448c95c51b0cf9b5035df4065cd8f62c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0504952102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0504952102%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2005%26volume%3D102%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=225-235&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D225%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lj2XEQSMy14pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robubi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3915</span><span class="NLM_x">–</span> <span class="NLM_lpage">3926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9002928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3915-3926&author=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=J.+R.+Simardauthor=S.+Kl%C3%BCterauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=A.+Robubiauthor=D.+Rauh&title=Hybrid+compound+design+to+overcome+the+gatekeeper+T338M+mutation+in+cSrc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc</span></div><div class="casAuthors">Getlik, Matthaeus; Gruetter, Christian; Simard, Jeffrey R.; Kluter, Sabine; Rabiller, Matthias; Rode, Haridas B.; Robubi, Armin; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3915-3926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments.  Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance.  Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed to develop these scaffolds into potent type II kinase inhibitors.  One of these compds., I (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc.  Details gleaned from crystal structures revealed a key feature of a subset of these compds., a surprising flexibility in the vicinity of the gatekeeper residue that allows these compds. to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-72ZDo25pC7Vg90H21EOLACvtfcHk0lj2XEQSMy14pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D&md5=3ff187e49298ec4690c76a2bc2100274</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002928%26sid%3Dliteratum%253Aachs%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRobubi%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHybrid%2520compound%2520design%2520to%2520overcome%2520the%2520gatekeeper%2520T338M%2520mutation%2520in%2520cSrc%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3915%26epage%3D3926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation from chemo-genomics profiling</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=859-862&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=J.+Y.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Insights+into+the+limited+activity+of+irreversible+EGFR+inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation+from+chemo-genomics+profiling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%2520from%2520chemo-genomics%2520profiling%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D859%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, E. S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span> </span><span class="NLM_article-title">Design and structure−activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">5369</span><span class="NLM_x">–</span> <span class="NLM_lpage">5389</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990345w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=5369-5389&author=L.+F.+Hennequinauthor=A.+P.+Thomasauthor=C.+Johnstoneauthor=E.+S.+E.+Stokesauthor=P.+A.+Pleauthor=J.+J.+M.+Lohmannauthor=D.+J.+Ogilvieauthor=M.+Dukesauthor=S.+R.+Wedgeauthor=J.+O.+Curwenauthor=J.+Kendrewauthor=C.+Lambert-van+der+Brempt&title=Design+and+structure%E2%88%92activity+relationship+of+a+new+class+of+potent+VEGF+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm990345w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990345w%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DStokes%26aufirst%3DE.%2BS.%2BE.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DLohmann%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26atitle%3DDesign%2520and%2520structure%25E2%2588%2592activity%2520relationship%2520of%2520a%2520new%2520class%2520of%2520potent%2520VEGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D5369%26epage%3D5389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Furuta, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, A.</span><span> </span><span class="NLM_article-title">Identification of potent and selective inhibitors of PDGF receptor autophosphorylation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2186</span><span class="NLM_x">–</span> <span class="NLM_lpage">2192</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0506423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2186-2192&author=T.+Furutaauthor=T.+Sakaiauthor=T.+Sengaauthor=T.+Osawaauthor=K.+Kuboauthor=T.+Shimizuauthor=R.+Suzukiauthor=T.+Yoshinoauthor=M.+Endoauthor=A.+Miwa&title=Identification+of+potent+and+selective+inhibitors+of+PDGF+receptor+autophosphorylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm0506423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0506423%26sid%3Dliteratum%253Aachs%26aulast%3DFuruta%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DOsawa%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DEndo%26aufirst%3DM.%26aulast%3DMiwa%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520PDGF%2520receptor%2520autophosphorylation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2186%26epage%3D2192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naquvi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Design of a displacement assay for kinases based on a DFG-out binding probe</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=357-367&author=S.+Kl%C3%BCterauthor=C.+Gr%C3%BCtterauthor=T.+Naquviauthor=M.+Rabillerauthor=J.+R.+Simardauthor=V.+Pawarauthor=M.+Getlikauthor=D.+Rauh&title=Design+of+a+displacement+assay+for+kinases+based+on+a+DFG-out+binding+probe"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DNaquvi%26aufirst%3DT.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DDesign%2520of%2520a%2520displacement%2520assay%2520for%2520kinases%2520based%2520on%2520a%2520DFG-out%2520binding%2520probe%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D53%26spage%3D357%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPietro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, R.</span><span> </span><span class="NLM_article-title">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1667</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701097z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1649-1667&author=J.-C.+Harmangeauthor=M.+M.+Weissauthor=J.+Germainauthor=A.+J.+Polverinoauthor=G.+Borgauthor=J.+Breadyauthor=D.+Chenauthor=D.+Choquetteauthor=A.+Coxonauthor=T.+DeMelfiauthor=L.+DiPietroauthor=N.+Doerrauthor=J.+Estradaauthor=J.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=S.+Kaufmanauthor=D.+S.+Laauthor=A.+Longauthor=M.+W.+Martinauthor=S.+Neervannanauthor=V.+F.+Patelauthor=M.+Potashmanauthor=K.+Regalauthor=P.+M.+Rovetoauthor=M.+L.+Schragauthor=C.+Starnesauthor=A.+Taskerauthor=Y.+Tefferaauthor=L.+Wangauthor=R.+D.+Whiteauthor=D.+A.+Whittingtonauthor=R.+Zanon&title=Naphthamides+as+Novel+and+Potent+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors%3A+Design%2C+Synthesis%2C+and+Evaluation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation</span></div><div class="casAuthors">Harmange, Jean-Christophe; Weiss, Matthew M.; Germain, Julie; Polverino, Anthony J.; Borg, George; Bready, James; Chen, Danlin; Choquette, Deborah; Coxon, Angela; DeMelfi, Tom; DiPietro, Lucian; Doerr, Nicholas; Estrada, Juan; Flynn, Julie; Graceffa, Russell F.; Harriman, Shawn P.; Kaufman, Stephen; La, Daniel S.; Long, Alexander; Martin, Matthew W.; Neervannan, Sesha; Patel, Vinod F.; Potashman, Michele; Regal, Kelly; Roveto, Phillip M.; Schrag, Michael L.; Starnes, Charlie; Tasker, Andrew; Teffera, Yohannes; Wang, Ling; White, Ryan D.; Whittington, Douglas A.; Zanon, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1649-1667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of naphthyl-based compds. were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors.  Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family.  Numerous analogs demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compds. possessed favorable pharmacokinetic (PK) profiles.  In particular, compd. I demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice.  A full account of the prepn., structure-activity relationships, pharmacokinetic properties, and pharmacol. of analogs within this series is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1vrmtgp3_m7Vg90H21EOLACvtfcHk0lijQopSsjaCFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D&md5=25685f28450b2ab132ffd278e6c53598</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm701097z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701097z%26sid%3Dliteratum%253Aachs%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DBorg%26aufirst%3DG.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDiPietro%26aufirst%3DL.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLong%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DSchrag%26aufirst%3DM.%2BL.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZanon%26aufirst%3DR.%26atitle%3DNaphthamides%2520as%2520Novel%2520and%2520Potent%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1649%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Bridges, A. J.; Denny, W. A.; Dobrusin, E. M.; Doherty, A. M.; Fry, D. W.; McNamara, D. J.; Showalter, H. D. H.; Smaill, J. B.; Zhou, H.</span><span class="NLM_etal">et al.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors</span>. U.S. Patent 97-US5778 9738983, 19970408,<span class="NLM_x"> </span><span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=A.+J.+Bridges&author=W.+A.+Denny&author=E.+M.+Dobrusin&author=A.+M.+Doherty&author=D.+W.+Fry&author=D.+J.+McNamara&author=H.+D.+H.+Showalter&author=J.+B.+Smaill&author=H.+Zhou&title=Preparation+of+N-quinazolinylacrylamides+and+analogs+as+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26atitle%3DPreparation%2520of%2520N-quinazolinylacrylamides%2520and%2520analogs%2520as%2520tyrosine%2520kinase%2520inhibitors%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frommolt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuckrath, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beroukhim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winckler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFramboise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahnenfuhrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhaak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=1727-1740&author=M.+L.+Sosauthor=K.+Michelauthor=T.+Zanderauthor=J.+Weissauthor=P.+Frommoltauthor=M.+Peiferauthor=D.+Liauthor=R.+Ullrichauthor=M.+Kokerauthor=F.+Fischerauthor=T.+Shimamuraauthor=D.+Rauhauthor=C.+Mermelauthor=S.+Fischerauthor=I.+Stuckrathauthor=S.+Heynckauthor=R.+Beroukhimauthor=W.+Linauthor=W.+Wincklerauthor=K.+Shahauthor=T.+LaFramboiseauthor=W.+F.+Moriartyauthor=M.+Hannaauthor=L.+Tolosiauthor=J.+Rahnenfuhrerauthor=R.+Verhaakauthor=D.+Chiangauthor=G.+Getzauthor=M.+Hellmichauthor=J.+Wolfauthor=L.+Girardauthor=M.+Peytonauthor=B.+A.+Weirauthor=T.+H.+Chenauthor=H.+Greulichauthor=J.+Barretinaauthor=G.+I.+Shapiroauthor=L.+A.+Garrawayauthor=A.+F.+Gazdarauthor=J.+D.+Minnaauthor=M.+Meyersonauthor=K.+K.+Wongauthor=R.+K.+Thomas&title=Predicting+drug+susceptibility+of+non-small+cell+lung+cancers+based+on+genetic+lesions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DMichel%26aufirst%3DK.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DFrommolt%26aufirst%3DP.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DUllrich%26aufirst%3DR.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DStuckrath%26aufirst%3DI.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DMoriarty%26aufirst%3DW.%2BF.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DTolosi%26aufirst%3DL.%26aulast%3DRahnenfuhrer%26aufirst%3DJ.%26aulast%3DVerhaak%26aufirst%3DR.%26aulast%3DChiang%26aufirst%3DD.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DHellmich%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DPredicting%2520drug%2520susceptibility%2520of%2520non-small%2520cell%2520lung%2520cancers%2520based%2520on%2520genetic%2520lesions%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D1727%26epage%3D1740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glatt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.4161%2Fcbt.6.5.4003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=17495523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyrsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=661-667&author=Y.+Yuzaauthor=K.+A.+Glattauthor=J.+R.+Jiangauthor=H.+Greulichauthor=Y.+Minamiauthor=M.+S.+Wooauthor=T.+Shimamuraauthor=G.+Shapiroauthor=J.+C.+Leeauthor=H.+B.+Jiauthor=W.+Fengauthor=T.+H.+Chenauthor=H.+Yanagisawaauthor=K.+K.+Wongauthor=M.+Meyerson&title=Allele-dependent+variation+in+the+relative+cellular+potency+of+distinct+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors</span></div><div class="casAuthors">Yuza, Yuki; Glatt, Karen A.; Jiang, Jingrui; Greulich, Heidi; Minami, Yuko; Woo, Michele S.; Shimamura, Takeshi; Shapiro, Geoffrey; Lee, Jeffrey C.; Ji, Hongbin; Feng, Whei; Chen, Tzu-Hsiu; Yanagisawa, Haruhiko; Wong, Kwok-Kin; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">661-667</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Targeted cancer therapies impede cancer cell growth by inhibiting the function of activated oncogene products.  Patients with non-small cell lung cancer and somatic mutations of EGFR can have a dramatic response to treatment with erlotinib and gefitinib; different somatic mutations are assocd. with different times to progression and survival.  In this study, the relative and abs. potencies of two distinct EGFR tyrosine kinase inhibitors, erlotinib and an investigational irreversible inhibitor, HKI-272, were found to vary significantly in a panel of Ba/F3 cells transformed by representative EGFR somatic mutations.  HKI-272 more potently inhibited the primary exon 20 insertion mutants, the secondary erlotinib-resistance mutants including T790M and many erlotinib-sensitive mutants including L858R.  In contrast, erlotinib is a more potent inhibitor of the major exon 19 deletion mutants than is HKI-272.  Analyses of EGFR autophosphorylation patterns confirmed the mutation-specific variation in relative potency of these tyrosine kinase inhibitors.  Our finding that distinct EGFR inhibitors are more effective in vitro for different mutant forms of the protein suggests that tyrosine kinase inhibitor treatment could be tailored to specific EGFR mutations.  More broadly, these results imply that the development and deployment of targeted therapies should focus on inhibition of specific cancer-causing mutations, not only on the mutated target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQZ-_1zRKrsrVg90H21EOLACvtfcHk0ljHUmifaLdjUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyrsrvM&md5=1be5784f5c44158dc72af4476ca46d67</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.4161%2Fcbt.6.5.4003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.6.5.4003%26sid%3Dliteratum%253Aachs%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DGlatt%26aufirst%3DK.%2BA.%26aulast%3DJiang%26aufirst%3DJ.%2BR.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DJi%26aufirst%3DH.%2BB.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DYanagisawa%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DAllele-dependent%2520variation%2520in%2520the%2520relative%2520cellular%2520potency%2520of%2520distinct%2520EGFR%2520inhibitors%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D661%26epage%3D667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frommolt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashkar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3256</span><span class="NLM_x">–</span> <span class="NLM_lpage">3261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3256-3261&author=M.+L.+Sosauthor=M.+Kokerauthor=B.+A.+Weirauthor=S.+Heynckauthor=R.+Rabinovskyauthor=T.+Zanderauthor=J.+M.+Seegerauthor=J.+Weissauthor=F.+Fischerauthor=P.+Frommoltauthor=K.+Michelauthor=M.+Peiferauthor=C.+Mermelauthor=L.+Girardauthor=M.+Peytonauthor=A.+F.+Gazdarauthor=J.+D.+Minnaauthor=L.+A.+Garrawayauthor=H.+Kashkarauthor=W.+Paoauthor=M.+Meyersonauthor=R.+K.+Thomas&title=PTEN+Loss+Contributes+to+Erlotinib+Resistance+in+EGFR-Mutant+Lung+Cancer+by+Activation+of+Akt+and+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DRabinovsky%26aufirst%3DR.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DSeeger%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DFrommolt%26aufirst%3DP.%26aulast%3DMichel%26aufirst%3DK.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DKashkar%26aufirst%3DH.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DPTEN%2520Loss%2520Contributes%2520to%2520Erlotinib%2520Resistance%2520in%2520EGFR-Mutant%2520Lung%2520Cancer%2520by%2520Activation%2520of%2520Akt%2520and%2520EGFR%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D3256%26epage%3D3261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1038%2Fnchembio866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=17334377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=229-238&author=J.+A.+Blairauthor=D.+Rauhauthor=C.+Kungauthor=C.+H.+Yunauthor=Q.+W.+Fanauthor=H.+Rodeauthor=C.+Zhangauthor=M.+J.+Eckauthor=W.+A.+Weissauthor=K.+M.+Shokat&title=Structure-guided+development+of+affinity+probes+for+tyrosine+kinases+using+chemical+genetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span></div><div class="casAuthors">Blair, Jimmy A.; Rauh, Daniel; Kung, Charles; Yun, Cai-Hong; Fan, Qi-Wen; Rode, Haridas; Zhang, Chao; Eck, Michael J.; Weiss, William A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-mol. inhibitors.  The authors report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue.  Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Cocrystal structures of two irreversible quinazoline inhibitors (I, II) bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Based on these structures, the authors developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe (III) to report the fraction of kinase necessary for cellular signaling, and the authors used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0KmYAm-skrVg90H21EOLACvtfcHk0lhv-Eta5Vq4oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D&md5=ce4d24a8d65d7080645bf382cd65dbca</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio866%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DFan%26aufirst%3DQ.%2BW.%26aulast%3DRode%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DStructure-guided%2520development%2520of%2520affinity%2520probes%2520for%2520tyrosine%2520kinases%2520using%2520chemical%2520genetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 37 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Christopher R. M. Asquith, Kaleb M. Naegeli, Michael P. East, Tuomo Laitinen, Tammy M. Havener, Carrow I. Wells, Gary L. Johnson, David H. Drewry, William J. Zuercher, <span class="NLM_string-name hlFld-ContribAuthor">David C. Morris</span>. </span><span class="cited-content_cbyCitation_article-title">Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4772-4778. <a href="https://doi.org/10.1021/acs.jmedchem.9b00350" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00350</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00350%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Ba%252BCyclin%252BG%252BAssociated%252BKinase%252B%252528GAK%252529%25252FEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitor%252BSet%252Bto%252BInterrogate%252Bthe%252BRelationship%252Bof%252BEGFR%252Band%252BGAK%252Bin%252BChordoma%26aulast%3DAsquith%26aufirst%3DChristopher%2BR.%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25022019%26date%3D19042019%26date%3D11042019%26volume%3D62%26issue%3D9%26spage%3D4772%26epage%3D4778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Deheng  Sun</span>, <span class="hlFld-ContribAuthor ">Yi  Tong</span>, <span class="hlFld-ContribAuthor ">Yuqiong  Xu</span>, <span class="hlFld-ContribAuthor ">Haiyang  Chen</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>, and <span class="hlFld-ContribAuthor ">Honglin  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (15)
                                     , 7111-7124. <a href="https://doi.org/10.1021/acs.jmedchem.6b00403" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00403%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BStructural%252BOptimization%252Bof%252BN5-Substituted%252B6%25252C7-Dioxo-6%25252C7-dihydropteridines%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DHao%26aufirst%3DYongjia%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26032016%26date%3D21072016%26date%3D11082016%26date%3D11072016%26volume%3D59%26issue%3D15%26spage%3D7111%26epage%3D7124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Grütter</span>, <span class="hlFld-ContribAuthor ">Jeffrey R.  Simard</span>, <span class="hlFld-ContribAuthor ">Svenja C.  Mayer-Wrangowski</span>, <span class="hlFld-ContribAuthor ">Peter H.  Schreier</span>, <span class="hlFld-ContribAuthor ">José  Pérez-Martín</span>, <span class="hlFld-ContribAuthor ">André  Richters</span>, <span class="hlFld-ContribAuthor ">Matthäus  Getlik</span>, <span class="hlFld-ContribAuthor ">Oliver  Gutbrod</span>, <span class="hlFld-ContribAuthor ">Christoph A.  Braun</span>, <span class="hlFld-ContribAuthor ">Michael E.  Beck</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting GSK3 from Ustilago maydis: Type-II Kinase Inhibitors as Potential Antifungals. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2012,</strong> <em>7 </em>
                                    (7)
                                     , 1257-1267. <a href="https://doi.org/10.1021/cb300128b" title="DOI URL">https://doi.org/10.1021/cb300128b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb300128b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb300128b%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DTargeting%252BGSK3%252Bfrom%252BUstilago%252Bmaydis%25253A%252BType-II%252BKinase%252BInhibitors%252Bas%252BPotential%252BAntifungals%26aulast%3DGr%25C3%25BCtter%26aufirst%3DChristian%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D19032012%26date%3D30042012%26date%3D15052012%26date%3D20072012%26date%3D30042012%26volume%3D7%26issue%3D7%26spage%3D1257%26epage%3D1267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mostafa M.  Elbadawi</span>, <span class="hlFld-ContribAuthor ">Wagdy M.  Eldehna</span>, <span class="hlFld-ContribAuthor ">Wenjie  Wang</span>, <span class="hlFld-ContribAuthor ">Keli K.  Agama</span>, <span class="hlFld-ContribAuthor ">Yves  Pommier</span>, <span class="hlFld-ContribAuthor ">Manabu  Abe</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113261. <a href="https://doi.org/10.1016/j.ejmech.2021.113261" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113261</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113261%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-alkoxy-2-aryl-6%25252C7-dimethoxyquinolines%252Bas%252Ba%252Bnew%252Bclass%252Bof%252Btopoisomerase%252BI%252Binhibitors%252Bendowed%252Bwith%252Bpotent%252Bin%2525C2%2525A0vitro%252Banticancer%252Bactivity%26aulast%3DElbadawi%26aufirst%3DMostafa%2BM.%26date%3D2021%26volume%3D215%26spage%3D113261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanna  Mao</span>, <span class="hlFld-ContribAuthor ">Kunjal  Soni</span>, <span class="hlFld-ContribAuthor ">Chetan  Sangani</span>, <span class="hlFld-ContribAuthor ">Yongfang  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">An Overview of Privileged Scaffold: Quinolines and Isoquinolines in Medicinal Chemistry as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (28)
                                     , 2599-2633. <a href="https://doi.org/10.2174/1568026620999200917154225" title="DOI URL">https://doi.org/10.2174/1568026620999200917154225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620999200917154225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620999200917154225%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DAn%252BOverview%252Bof%252BPrivileged%252BScaffold%25253A%252BQuinolines%252Band%252BIsoquinolines%252Bin%252BMedicinal%252BChemistry%252Bas%252BAnticancer%252BAgents%26aulast%3DMao%26aufirst%3DYanna%26date%3D2020%26volume%3D20%26issue%3D28%26spage%3D2599%26epage%3D2633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wafaa A.  Ewes</span>, <span class="hlFld-ContribAuthor ">Mohammad A.  Elmorsy</span>, <span class="hlFld-ContribAuthor ">Shahenda M.  El-Messery</span>, <span class="hlFld-ContribAuthor ">Magda N.A.  Nasr</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, biological evaluation and molecular modeling study of [1,2,4]-Triazolo[4,3-c]quinazolines: New class of EGFR-TK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (7)
                                     , 115373. <a href="https://doi.org/10.1016/j.bmc.2020.115373" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115373%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bmodeling%252Bstudy%252Bof%252B%25255B1%25252C2%25252C4%25255D-Triazolo%25255B4%25252C3-c%25255Dquinazolines%25253A%252BNew%252Bclass%252Bof%252BEGFR-TK%252Binhibitors%26aulast%3DEwes%26aufirst%3DWafaa%2BA.%26date%3D2020%26volume%3D28%26issue%3D7%26spage%3D115373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammed A.I.  Elbastawesy</span>, <span class="hlFld-ContribAuthor ">Ashraf A.  Aly</span>, <span class="hlFld-ContribAuthor ">Mohamed  Ramadan</span>, <span class="hlFld-ContribAuthor ">Yaseen A.M.M.  Elshaier</span>, <span class="hlFld-ContribAuthor ">Bahaa G.M.  Youssif</span>, <span class="hlFld-ContribAuthor ">Alan B.  Brown</span>, <span class="hlFld-ContribAuthor ">Gamal  El-Din A Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>90 </em>, 103045. <a href="https://doi.org/10.1016/j.bioorg.2019.103045" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252BPyrazoloquinolin-2-ones%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bdocking%252Bstudies%25252C%252Band%252Bbiological%252Bevaluation%252Bas%252Bantiproliferative%252BEGFR-TK%252Binhibitors%26aulast%3DElbastawesy%26aufirst%3DMohammed%2BA.I.%26date%3D2019%26volume%3D90%26spage%3D103045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aiten M.  Soliman</span>, <span class="hlFld-ContribAuthor ">Mostafa M.  Ghorab</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>88 </em>, 102956. <a href="https://doi.org/10.1016/j.bioorg.2019.102956" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.102956</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.102956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.102956%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DExploration%252Bof%252BN-alkyl-2-%25255B%2525284-oxo-3-%2525284-sulfamoylphenyl%252529-3%25252C4-dihydroquinazolin-2-yl%252529thio%25255Dacetamide%252Bderivatives%252Bas%252Banticancer%252Band%252Bradiosensitizing%252Bagents%26aulast%3DSoliman%26aufirst%3DAiten%2BM.%26date%3D2019%26volume%3D88%26spage%3D102956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikil  Purushotham</span>, <span class="hlFld-ContribAuthor ">Boja  Poojary</span>, <span class="hlFld-ContribAuthor ">Vaishali  Rai</span>, <span class="hlFld-ContribAuthor ">Sowmya Padejjar  Vasantha</span>. </span><span class="cited-content_cbyCitation_article-title">A preliminary study on quinazolinylaminobenzoyl monopeptide esters as effective Gram-positive bacteriostatic agents. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (5)
                                     , 407-422. <a href="https://doi.org/10.4155/fmc-2018-0275" title="DOI URL">https://doi.org/10.4155/fmc-2018-0275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0275%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DA%252Bpreliminary%252Bstudy%252Bon%252Bquinazolinylaminobenzoyl%252Bmonopeptide%252Besters%252Bas%252Beffective%252BGram-positive%252Bbacteriostatic%252Bagents%26aulast%3DPurushotham%26aufirst%3DNikil%26date%3D2019%26volume%3D11%26issue%3D5%26spage%3D407%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bingbing  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Jianguo  Qi</span>, <span class="hlFld-ContribAuthor ">Rong  Luo</span>, <span class="hlFld-ContribAuthor ">Zhou  Lan</span>, <span class="hlFld-ContribAuthor ">Yanzhuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaohan  Hu</span>, <span class="hlFld-ContribAuthor ">Qidong  Tang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 367-380. <a href="https://doi.org/10.1016/j.ejmech.2018.11.069" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.069%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BAZD9291%252Bderivatives%252Bas%252Bselective%252Band%252Bpotent%252BEGFRL858R%25252FT790M%252Binhibitors%26aulast%3DZhao%26aufirst%3DBingbing%26date%3D2019%26volume%3D163%26spage%3D367%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed Jawed  Ahsan</span>, <span class="hlFld-ContribAuthor ">Rupesh Kumar  Kumawat</span>, <span class="hlFld-ContribAuthor ">Surender Singh  Jadav</span>, <span class="hlFld-ContribAuthor ">Mohammed H.  Geesi</span>, <span class="hlFld-ContribAuthor ">Mohammed Afroz  Bakht</span>, <span class="hlFld-ContribAuthor ">Mohd. Zaheen  Hassan</span>, <span class="hlFld-ContribAuthor ">Abdulmalik Bin Saleh  Al-Tamimi</span>, <span class="hlFld-ContribAuthor ">Yassine  Riadi</span>, <span class="hlFld-ContribAuthor ">Salahuddin</span>, <span class="hlFld-ContribAuthor ">Afzal  Hussain</span>, <span class="hlFld-ContribAuthor ">Narayan Murthy  Ganta</span>, <span class="hlFld-ContribAuthor ">Habibullah  Khalilullah</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Cytotoxic Evaluation, and Molecular Docking Studies of N-(7- hydroxy-4-methyl-2-oxoquinolin-1(2H)-yl)acetamide/benzamide Analogues. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2018,</strong> <em>16 </em>
                                    (2)
                                     , 182-193. <a href="https://doi.org/10.2174/1570180815666180501160047" title="DOI URL">https://doi.org/10.2174/1570180815666180501160047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180815666180501160047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180815666180501160047%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DSynthesis%25252C%252BCytotoxic%252BEvaluation%25252C%252Band%252BMolecular%252BDocking%252BStudies%252Bof%252BN-%2525287-%252Bhydroxy-4-methyl-2-oxoquinolin-1%2525282H%252529-yl%252529acetamide%25252Fbenzamide%252BAnalogues%26aulast%3DAhsan%26aufirst%3DMohamed%2BJawed%26date%3D2018%26volume%3D16%26issue%3D2%26spage%3D182%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priyanka  Bhatt</span>, <span class="hlFld-ContribAuthor ">Manoj  Kumar</span>, <span class="hlFld-ContribAuthor ">Anjali  Jha</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, docking and anticancer activity of azo-linked hybrids of 1,3,4-thia-/oxadiazoles with cyclic imides. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2018,</strong> <em>22 </em>
                                    (4)
                                     , 827-840. <a href="https://doi.org/10.1007/s11030-018-9832-5" title="DOI URL">https://doi.org/10.1007/s11030-018-9832-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-018-9832-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-018-9832-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%25252C%252Bdocking%252Band%252Banticancer%252Bactivity%252Bof%252Bazo-linked%252Bhybrids%252Bof%252B1%25252C3%25252C4-thia-%25252Foxadiazoles%252Bwith%252Bcyclic%252Bimides%26aulast%3DBhatt%26aufirst%3DPriyanka%26date%3D2018%26date%3D2018%26volume%3D22%26issue%3D4%26spage%3D827%26epage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rania S.M.  Ismail</span>, <span class="hlFld-ContribAuthor ">Sahar M.  Abou-Seri</span>, <span class="hlFld-ContribAuthor ">Wagdy M.  Eldehna</span>, <span class="hlFld-ContribAuthor ">Nasser S.M.  Ismail</span>, <span class="hlFld-ContribAuthor ">Sara M.  Elgazwi</span>, <span class="hlFld-ContribAuthor ">Hazem A.  Ghabbour</span>, <span class="hlFld-ContribAuthor ">Mahmoud Salama  Ahmed</span>, <span class="hlFld-ContribAuthor ">Fathi T.  Halaweish</span>, <span class="hlFld-ContribAuthor ">Dalal A.  Abou El Ella</span>. </span><span class="cited-content_cbyCitation_article-title">Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 782-796. <a href="https://doi.org/10.1016/j.ejmech.2018.06.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.06.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.06.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bseries%252Bof%252B6-%2525282-substitutedacetamido%252529-4-anilinoquinazolines%252Bas%252BEGFR-ERK%252Bsignal%252Btransduction%252Binhibitors%252Bin%252BMCF-7%252Bbreast%252Bcancer%252Bcells%26aulast%3DIsmail%26aufirst%3DRania%2BS.M.%26date%3D2018%26volume%3D155%26spage%3D782%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher R. M.  Asquith</span>, <span class="hlFld-ContribAuthor ">Tuomo  Laitinen</span>, <span class="hlFld-ContribAuthor ">James M.  Bennett</span>, <span class="hlFld-ContribAuthor ">Paulo H.  Godoi</span>, <span class="hlFld-ContribAuthor ">Michael P.  East</span>, <span class="hlFld-ContribAuthor ">Graham J.  Tizzard</span>, <span class="hlFld-ContribAuthor ">Lee M.  Graves</span>, <span class="hlFld-ContribAuthor ">Gary L.  Johnson</span>, <span class="hlFld-ContribAuthor ">Ronna E.  Dornsife</span>, <span class="hlFld-ContribAuthor ">Carrow I.  Wells</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Elkins</span>, <span class="hlFld-ContribAuthor ">Timothy M.  Willson</span>, <span class="hlFld-ContribAuthor ">William J.  Zuercher</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (1)
                                     , 48-66. <a href="https://doi.org/10.1002/cmdc.201700663" title="DOI URL">https://doi.org/10.1002/cmdc.201700663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700663%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DIdentification%252Band%252BOptimization%252Bof%252B4-Anilinoquinolines%252Bas%252BInhibitors%252Bof%252BCyclin%2525E2%252580%252585G%252BAssociated%252BKinase%26aulast%3DAsquith%26aufirst%3DChristopher%2BR.%2BM.%26date%3D2018%26date%3D2017%26volume%3D13%26issue%3D1%26spage%3D48%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magda A.-A.  El-Sayed</span>, <span class="hlFld-ContribAuthor ">Walaa M.  El-Husseiny</span>, <span class="hlFld-ContribAuthor ">Naglaa I.  Abdel-Aziz</span>, <span class="hlFld-ContribAuthor ">Adel S.  El-Azab</span>, <span class="hlFld-ContribAuthor ">Hatem A.  Abuelizz</span>, <span class="hlFld-ContribAuthor ">Alaa A.-M.  Abdel-Aziz</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2018,</strong> <em>33 </em>
                                    (1)
                                     , 199-209. <a href="https://doi.org/10.1080/14756366.2017.1407926" title="DOI URL">https://doi.org/10.1080/14756366.2017.1407926</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2017.1407926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2017.1407926%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-styrylquinolines%252Bas%252Bantitumour%252Bagents%252Band%252BEGFR%252Bkinase%252Binhibitors%25253A%252Bmolecular%252Bdocking%252Bstudy%26aulast%3DEl-Sayed%26aufirst%3DMagda%2BA.-A.%26date%3D2018%26date%3D2017%26volume%3D33%26issue%3D1%26spage%3D199%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramalingam  Boobalan</span>, <span class="hlFld-ContribAuthor ">Kuang-Kai  Liu</span>, <span class="hlFld-ContribAuthor ">Jui-I.  Chao</span>, <span class="hlFld-ContribAuthor ">Chinpiao  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (8)
                                     , 1784-1788. <a href="https://doi.org/10.1016/j.bmcl.2017.02.059" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.02.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.02.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.02.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bassay%252Bof%252Berlotinib%252Banalogues%252Band%252BBSA-conjugated%252Berlotinib%252Banalogue%26aulast%3DBoobalan%26aufirst%3DRamalingam%26date%3D2017%26volume%3D27%26issue%3D8%26spage%3D1784%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Tridente</span>. </span><span class="cited-content_cbyCitation_article-title">Erlotinib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 145-165. <a href="https://doi.org/10.1016/B978-0-12-809400-6.00007-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-809400-6.00007-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809400-6.00007-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809400-6.00007-X%26sid%3Dliteratum%253Aachs%26atitle%3DErlotinib%26aulast%3DTridente%26aufirst%3DGiuseppe%26date%3D2017%26spage%3D145%26epage%3D165%26pub%3DElsevier%26atitle%3DAdverse%252BEvents%252Band%252BOncotargeted%252BKinase%252BInhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Fei-Hu  Gong</span>, <span class="hlFld-ContribAuthor ">Ji-Qing  Ye</span>, <span class="hlFld-ContribAuthor ">Chi  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Chuan-Gui  Li</span>, <span class="hlFld-ContribAuthor ">Yun-Gen  Xu</span>, <span class="hlFld-ContribAuthor ">Li-Ping  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>125 </em>, 245-254. <a href="https://doi.org/10.1016/j.ejmech.2016.09.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.09.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.09.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.09.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bdiscovery%252Bof%252B4-anilinoquinazoline-urea%252Bderivatives%252Bas%252Bdual%252BTK%252Binhibitors%252Bof%252BEGFR%252Band%252BVEGFR-2%26aulast%3DZhang%26aufirst%3DHai-Qi%26date%3D2017%26volume%3D125%26spage%3D245%26epage%3D254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Liu</span>, <span class="hlFld-ContribAuthor ">Tian  Luan</span>, <span class="hlFld-ContribAuthor ">Jian  Kong</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai-Feng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Anti-Tumor Activities of 4-Anilinoquinoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (1)
                                     , 21. <a href="https://doi.org/10.3390/molecules21010021" title="DOI URL">https://doi.org/10.3390/molecules21010021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21010021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21010021%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BAnti-Tumor%252BActivities%252Bof%252B4-Anilinoquinoline%252BDerivatives%26aulast%3DLiu%26aufirst%3DDan%26date%3D2016%26date%3D2015%26volume%3D21%26issue%3D1%26spage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Obaid  Afzal</span>, <span class="hlFld-ContribAuthor ">Suresh  Kumar</span>, <span class="hlFld-ContribAuthor ">Md Rafi  Haider</span>, <span class="hlFld-ContribAuthor ">Md Rahmat  Ali</span>, <span class="hlFld-ContribAuthor ">Rajiv  Kumar</span>, <span class="hlFld-ContribAuthor ">Manu  Jaggi</span>, <span class="hlFld-ContribAuthor ">Sandhya  Bawa</span>. </span><span class="cited-content_cbyCitation_article-title">A review on anticancer potential of bioactive heterocycle quinoline. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>97 </em>, 871-910. <a href="https://doi.org/10.1016/j.ejmech.2014.07.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Banticancer%252Bpotential%252Bof%252Bbioactive%252Bheterocycle%252Bquinoline%26aulast%3DAfzal%26aufirst%3DObaid%26date%3D2015%26volume%3D97%26spage%3D871%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arumugam  Sudha</span>, <span class="hlFld-ContribAuthor ">Pappu  Srinivasan</span>, <span class="hlFld-ContribAuthor ">Palanivel  Rameshthangam</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2015,</strong> <em>35 </em>
                                    (2)
                                     , 137-148. <a href="https://doi.org/10.3109/10799893.2014.942461" title="DOI URL">https://doi.org/10.3109/10799893.2014.942461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/10799893.2014.942461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F10799893.2014.942461%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DExploration%252Bof%252Bpotential%252BEGFR%252Binhibitors%25253A%252Ba%252Bcombination%252Bof%252Bpharmacophore-based%252Bvirtual%252Bscreening%25252C%252Batom-based%252B3D-QSAR%252Band%252Bmolecular%252Bdocking%252Banalysis%26aulast%3DSudha%26aufirst%3DArumugam%26date%3D2015%26date%3D2014%26volume%3D35%26issue%3D2%26spage%3D137%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia  Spanò</span>, <span class="hlFld-ContribAuthor ">Alessandra  Montalbano</span>, <span class="hlFld-ContribAuthor ">Anna  Carbone</span>, <span class="hlFld-ContribAuthor ">Barbara  Parrino</span>, <span class="hlFld-ContribAuthor ">Patrizia  Diana</span>, <span class="hlFld-ContribAuthor ">Girolamo  Cirrincione</span>, <span class="hlFld-ContribAuthor ">Ignazio  Castagliuolo</span>, <span class="hlFld-ContribAuthor ">Paola  Brun</span>, <span class="hlFld-ContribAuthor ">Olaf-Georg  Issinger</span>, <span class="hlFld-ContribAuthor ">Silvia  Tisi</span>, <span class="hlFld-ContribAuthor ">Irina  Primac</span>, <span class="hlFld-ContribAuthor ">Daniela  Vedaldi</span>, <span class="hlFld-ContribAuthor ">Alessia  Salvador</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of a new class of pyrrolo[3,4-h]quinazolines with antimitotic activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>74 </em>, 340-357. <a href="https://doi.org/10.1016/j.ejmech.2013.10.014" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.10.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.10.014%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252Ba%252Bnew%252Bclass%252Bof%252Bpyrrolo%25255B3%25252C4-h%25255Dquinazolines%252Bwith%252Bantimitotic%252Bactivity%26aulast%3DSpan%25C3%25B2%26aufirst%3DVirginia%26date%3D2014%26volume%3D74%26spage%3D340%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si-Ning  Li</span>, <span class="hlFld-ContribAuthor ">Huan-Qiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor inhibitors: a patent review (2010 – present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (3)
                                     , 309-321. <a href="https://doi.org/10.1517/13543776.2014.871527" title="DOI URL">https://doi.org/10.1517/13543776.2014.871527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.871527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.871527%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DLi%26aufirst%3DSi-Ning%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D309%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Ya-Juan  Qin</span>, <span class="hlFld-ContribAuthor ">Jian  Sun</span>, <span class="hlFld-ContribAuthor ">Jing-Ran  Li</span>, <span class="hlFld-ContribAuthor ">Fei  Fang</span>, <span class="hlFld-ContribAuthor ">Qian-Ru  Du</span>, <span class="hlFld-ContribAuthor ">Yong  Qian</span>, <span class="hlFld-ContribAuthor ">Hai-Bin  Gong</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>, . </span><span class="cited-content_cbyCitation_article-title">Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2013,</strong> <em>8 </em>
                                    (8)
                                     , e69427. <a href="https://doi.org/10.1371/journal.pone.0069427" title="DOI URL">https://doi.org/10.1371/journal.pone.0069427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0069427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0069427%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DOptimization%252Bof%252BSubstituted%252B6-Salicyl-4-Anilinoquinazoline%252BDerivatives%252Bas%252BDual%252BEGFR%25252FHER2%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DLi%26aufirst%3DDong-Dong%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D8%26spage%3De69427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marawan  Ahmed</span>, <span class="hlFld-ContribAuthor ">Maiada M.  Sadek</span>, <span class="hlFld-ContribAuthor ">Khaled A.  Abouzid</span>, <span class="hlFld-ContribAuthor ">Feng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">In silico design: Extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2013,</strong> <em>44 </em>, 220-231. <a href="https://doi.org/10.1016/j.jmgm.2013.06.004" title="DOI URL">https://doi.org/10.1016/j.jmgm.2013.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2013.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2013.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DIn%252Bsilico%252Bdesign%25253A%252BExtended%252Bmolecular%252Bdynamic%252Bsimulations%252Bof%252Ba%252Bnew%252Bseries%252Bof%252Bdually%252Bacting%252Binhibitors%252Bagainst%252BEGFR%252Band%252BHER2%26aulast%3DAhmed%26aufirst%3DMarawan%26date%3D2013%26volume%3D44%26spage%3D220%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergey I.  Kovalenko</span>, <span class="hlFld-ContribAuthor ">Inna S.  Nosulenko</span>, <span class="hlFld-ContribAuthor ">Alexey Yu.  Voskoboynik</span>, <span class="hlFld-ContribAuthor ">Galina G.  Berest</span>, <span class="hlFld-ContribAuthor ">Lyudmila N.  Antipenko</span>, <span class="hlFld-ContribAuthor ">Alexey N.  Antipenko</span>, <span class="hlFld-ContribAuthor ">Andrey M.  Katsev</span>. </span><span class="cited-content_cbyCitation_article-title">Novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides: synthesis, cytotoxicity, anticancer activity, COMPARE analysis and docking. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2013,</strong> <em>22 </em>
                                    (6)
                                     , 2610-2632. <a href="https://doi.org/10.1007/s00044-012-0257-x" title="DOI URL">https://doi.org/10.1007/s00044-012-0257-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-012-0257-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-012-0257-x%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DNovel%252BN-aryl%252528alkaryl%252529-2-%25255B%2525283-R-2-oxo-2H-%25255B1%25252C2%25252C4%25255Dtriazino%25255B2%25252C3-c%25255Dquinazoline-6-yl%252529thio%25255Dacetamides%25253A%252Bsynthesis%25252C%252Bcytotoxicity%25252C%252Banticancer%252Bactivity%25252C%252BCOMPARE%252Banalysis%252Band%252Bdocking%26aulast%3DKovalenko%26aufirst%3DSergey%2BI.%26date%3D2013%26date%3D2012%26volume%3D22%26issue%3D6%26spage%3D2610%26epage%3D2632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samar  Mowafy</span>, <span class="hlFld-ContribAuthor ">Nahla A.  Farag</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>61 </em>, 132-145. <a href="https://doi.org/10.1016/j.ejmech.2012.10.017" title="DOI URL">https://doi.org/10.1016/j.ejmech.2012.10.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2012.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2012.10.017%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bin%2525C2%2525A0vitro%252Banti-proliferative%252Bactivity%252Bof%252B4%25252C6-quinazolinediamines%252Bas%252Bpotent%252BEGFR-TK%252Binhibitors%26aulast%3DMowafy%26aufirst%3DSamar%26date%3D2013%26volume%3D61%26spage%3D132%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Ridong  Li</span>, <span class="hlFld-ContribAuthor ">Kang  Qiao</span>, <span class="hlFld-ContribAuthor ">Zemei  Ge</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>, <span class="hlFld-ContribAuthor ">Tieming  Cheng</span>, <span class="hlFld-ContribAuthor ">Runtao  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Dithiocarbamic Acid Esters Derived from 6-Aminomethyl-4-anilinoquinazolines and 6-Aminomethyl-4-anilino-3-cyanoquinolines as Potent EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2013,</strong> <em>346 </em>
                                    (1)
                                     , 44-52. <a href="https://doi.org/10.1002/ardp.201200267" title="DOI URL">https://doi.org/10.1002/ardp.201200267</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201200267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201200267%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DNovel%252BDithiocarbamic%252BAcid%252BEsters%252BDerived%252Bfrom%252B6-Aminomethyl-4-anilinoquinazolines%252Band%252B6-Aminomethyl-4-anilino-3-cyanoquinolines%252Bas%252BPotent%252BEGFR%252BInhibitors%26aulast%3DZhang%26aufirst%3DXin%26date%3D2013%26date%3D2012%26volume%3D346%26issue%3D1%26spage%3D44%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karl J.  Shaffer</span>, <span class="hlFld-ContribAuthor ">Daniel C.  Parr</span>, <span class="hlFld-ContribAuthor ">Marco  Wenzel</span>, <span class="hlFld-ContribAuthor ">Gareth J.  Rowlands</span>, <span class="hlFld-ContribAuthor ">Paul G.  Plieger</span>. </span><span class="cited-content_cbyCitation_article-title">The Proton Sponge Effect: Substitution of Quino[7,8-
              h
              ]quinoline and the First Structurally Characterised Derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2012,</strong> <em>2012 </em>
                                    (35)
                                     , 6967-6975. <a href="https://doi.org/10.1002/ejoc.201201131" title="DOI URL">https://doi.org/10.1002/ejoc.201201131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201201131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201201131%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DThe%252BProton%252BSponge%252BEffect%25253A%252BSubstitution%252Bof%252BQuino%25255B7%25252C8-%252Bh%252B%25255Dquinoline%252Band%252Bthe%252BFirst%252BStructurally%252BCharacterised%252BDerivatives%26aulast%3DShaffer%26aufirst%3DKarl%2BJ.%26date%3D2012%26date%3D2012%26volume%3D2012%26issue%3D35%26spage%3D6967%26epage%3D6975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaopeng  Chen</span>, <span class="hlFld-ContribAuthor ">Xuemin  Li</span>, <span class="hlFld-ContribAuthor ">Shengbiao  Wan</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Novel Benzoxazinone Compounds as Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2012,</strong> <em>42 </em>
                                    (19)
                                     , 2937-2946. <a href="https://doi.org/10.1080/00397911.2011.573169" title="DOI URL">https://doi.org/10.1080/00397911.2011.573169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2011.573169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2011.573169%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DSynthesis%252Bof%252BNovel%252BBenzoxazinone%252BCompounds%252Bas%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DChen%26aufirst%3DShaopeng%26date%3D2012%26volume%3D42%26issue%3D19%26spage%3D2937%26epage%3D2946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Johannes M.  Heuckmann</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>, <span class="hlFld-ContribAuthor ">Roman K.  Thomas</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Oncology</span><span> <strong>2012,</strong> <em>30 </em>
                                    (27)
                                     , 3417-3420. <a href="https://doi.org/10.1200/JCO.2012.43.1825" title="DOI URL">https://doi.org/10.1200/JCO.2012.43.1825</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/JCO.2012.43.1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FJCO.2012.43.1825%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Oncology%26atitle%3DEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BSignaling%252Band%252BCovalent%252BEGFR%252BInhibition%252Bin%252BLung%252BCancer%26aulast%3DHeuckmann%26aufirst%3DJohannes%2BM.%26date%3D2012%26volume%3D30%26issue%3D27%26spage%3D3417%26epage%3D3420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siyuan  Li</span>, <span class="hlFld-ContribAuthor ">Chunying  Guo</span>, <span class="hlFld-ContribAuthor ">Hongli  Zhao</span>, <span class="hlFld-ContribAuthor ">Yun  Tang</span>, <span class="hlFld-ContribAuthor ">Minbo  Lan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (2)
                                     , 877-885. <a href="https://doi.org/10.1016/j.bmc.2011.11.056" title="DOI URL">https://doi.org/10.1016/j.bmc.2011.11.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2011.11.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2011.11.056%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B4-%25255B3-chloro-4-%2525283-fluorobenzyloxy%252529anilino%25255D-6-%2525283-substituted-phenoxy%252529pyrimidines%252Bas%252Bdual%252BEGFR%25252FErbB-2%252Bkinase%252Binhibitors%26aulast%3DLi%26aufirst%3DSiyuan%26date%3D2012%26volume%3D20%26issue%3D2%26spage%3D877%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Galyna G.  Berest</span>, <span class="hlFld-ContribAuthor ">Olexii Yu.  Voskoboynik</span>, <span class="hlFld-ContribAuthor ">Sergiy I.  Kovalenko</span>, <span class="hlFld-ContribAuthor ">Olexii M.  Antypenko</span>, <span class="hlFld-ContribAuthor ">Inna S.  Nosulenko</span>, <span class="hlFld-ContribAuthor ">Andrii M.  Katsev</span>, <span class="hlFld-ContribAuthor ">Olena S.  Shandrovskaya</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>46 </em>
                                    (12)
                                     , 6066-6074. <a href="https://doi.org/10.1016/j.ejmech.2011.10.022" title="DOI URL">https://doi.org/10.1016/j.ejmech.2011.10.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2011.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2011.10.022%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivity%252Bof%252Bnovel%252BN-cycloalkyl-%252528cycloalkylaryl%252529-2-%25255B%2525283-R-2-oxo-2H-%25255B1%25252C2%25252C4%25255Dtriazino%25255B2%25252C3-c%25255Dquinazoline-6-yl%252529thio%25255Dacetamides%26aulast%3DBerest%26aufirst%3DGalyna%2BG.%26date%3D2011%26volume%3D46%26issue%3D12%26spage%3D6066%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Yang</span>, <span class="hlFld-ContribAuthor ">Liang-Hong  Guo</span>, <span class="hlFld-ContribAuthor ">Na  Qu</span>, <span class="hlFld-ContribAuthor ">Ming-Yuan  Wei</span>, <span class="hlFld-ContribAuthor ">Li-Xia  Zhao</span>, <span class="hlFld-ContribAuthor ">Bin  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">Label-free electrochemical measurement of protein tyrosine kinase activity and inhibition based on electro-catalyzed tyrosine signaling. </span><span class="cited-content_cbyCitation_journal-name">Biosensors and Bioelectronics</span><span> <strong>2011,</strong> <em>28 </em>
                                    (1)
                                     , 284-290. <a href="https://doi.org/10.1016/j.bios.2011.07.033" title="DOI URL">https://doi.org/10.1016/j.bios.2011.07.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bios.2011.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bios.2011.07.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBiosensors%2520and%2520Bioelectronics%26atitle%3DLabel-free%252Belectrochemical%252Bmeasurement%252Bof%252Bprotein%252Btyrosine%252Bkinase%252Bactivity%252Band%252Binhibition%252Bbased%252Bon%252Belectro-catalyzed%252Btyrosine%252Bsignaling%26aulast%3DYang%26aufirst%3DYu%26date%3D2011%26volume%3D28%26issue%3D1%26spage%3D284%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongying  Du</span>, <span class="hlFld-ContribAuthor ">Zhide  Hu</span>, <span class="hlFld-ContribAuthor ">Andrea  Bazzoli</span>, <span class="hlFld-ContribAuthor ">Yang  Zhang</span>, . </span><span class="cited-content_cbyCitation_article-title">Prediction of Inhibitory Activity of Epidermal Growth Factor Receptor Inhibitors Using Grid Search-Projection Pursuit Regression Method. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2011,</strong> <em>6 </em>
                                    (7)
                                     , e22367. <a href="https://doi.org/10.1371/journal.pone.0022367" title="DOI URL">https://doi.org/10.1371/journal.pone.0022367</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0022367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0022367%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DPrediction%252Bof%252BInhibitory%252BActivity%252Bof%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%252BUsing%252BGrid%252BSearch-Projection%252BPursuit%252BRegression%252BMethod%26aulast%3DDu%26aufirst%3DHongying%26date%3D2011%26date%3D2011%26volume%3D6%26issue%3D7%26spage%3De22367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ri-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiao-Yan  Li</span>, <span class="hlFld-ContribAuthor ">Ze-Mei  Ge</span>, <span class="hlFld-ContribAuthor ">Run-Tao  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (12)
                                     , 3637-3640. <a href="https://doi.org/10.1016/j.bmcl.2011.04.096" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.04.096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.04.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.04.096%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252BEGFR%252Binhibitors%252Bprepared%252Bby%252Bcombination%252Bof%252Bdithiocarbamic%252Bacid%252Besters%252Band%252B4-anilinoquinazolines%26aulast%3DLi%26aufirst%3DRi-Dong%26date%3D2011%26volume%3D21%26issue%3D12%26spage%3D3637%26epage%3D3640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haridas B.  Rode</span>, <span class="hlFld-ContribAuthor ">Martin L.  Sos</span>, <span class="hlFld-ContribAuthor ">Christian  Grütter</span>, <span class="hlFld-ContribAuthor ">Stefanie  Heynck</span>, <span class="hlFld-ContribAuthor ">Jeffrey R.  Simard</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2011,</strong> <em>19 </em>
                                    (1)
                                     , 429-439. <a href="https://doi.org/10.1016/j.bmc.2010.11.007" title="DOI URL">https://doi.org/10.1016/j.bmc.2010.11.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2010.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2010.11.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B7-substituted-1-%2525283-bromophenylamino%252529isoquinoline-4-carbonitriles%252Bas%252Binhibitors%252Bof%252Bmyosin%252Blight%252Bchain%252Bkinase%252Band%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DRode%26aufirst%3DHaridas%2BB.%26date%3D2011%26volume%3D19%26issue%3D1%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 4-anilinoquinazoline- and 4-anilinoquinoline-based EGFR/HER2 inhibitors. Simple 4-anilinoquinazolines such as <b>1</b> served as starting points for the development of potent type I and type II EGFR/HER2 inhibitors approved for the treatment of NSCLC. Erlotinib and Gefitinib are type I inhibitors and bind to the ATP site of activated kinases. Lapatinib is a type II inhibitor and stabilizes enzymatically inactive kinase conformations of EGFR and HER2. According to earlier studies, quinolines such as <b>2a</b> show reduced activity against EGFR and are less suited for compound optimization.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a><b>2b</b> represents a series of 6- and 7- substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR discussed in this study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding modes of 4-anilinoquinazoline- and 4-anilinoisoquinoline-based EGFR and HER2 inhibitors. (a) Proposed binding mode of a 4-anilinoquinazoline to the ATP-binding site of EGFR. Hydrogen bonding interactions of the inhibitor with the hinge region (pink) and the side chain of the gatekeeper residue Thr790 (mediated via a water molecule (W)) are shown as red dotted lines. (b) This binding mode stimulated the design and synthesis of 3-quinolinecarbonitriles to displace the proposed water molecule and to form a direct hydrogen bond to the side chain of gatekeeper residue (Thr790).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (c) The presence of a less conserved Cys at the lip of the ATP pocket fostered the development of irreversible quinazoline and isoquinoline EGFR inhibitors currently in clinical trials. The irreversible inhibitor Neratinib is modeled to the catalytic domain of EGFR. Modeling is based on the crystal structure of Neratinib in complex with drug resistant EGFR-Thr790Met (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV">2JIV</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The electrophile of the inhibitor forms a covalent bond with the side chain of Cys797. Cys797 is located at the N-terminal end of a short helix and activated by the helix dipole. Both reversible and irreversible 3-quinolinecarbonitriles were designed to (a) displace the water molecule (W10), and (b) to form a direct hydrogen bond to the side chain hydroxyl of the gatekeeper Thr790.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0009.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinoline and Quinazoline Derivatives I<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HNO<sub>3</sub>/H<sub>2</sub>SO<sub>4</sub>, −15 to 0 °C; (b) POCl<sub>3</sub>, cat. DMF, reflux; (c) 3-bromoaniline, cat. conc HCl, isopropyl alcohol, reflux; (d) DMF acetal, reflux; (e) 3-bromoaniline, HOAc, reflux; (f) Fe, HOAc, aq EtOH, reflux; (g) RCOCl, DIEA, THF, 0 °C to rt; (h) oxalyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, cat. DMF, reflux, 30 min. Compound <b>3f</b> was synthesized from <b>11b</b> and 4-(dimethylamino)butyric acid hydrochloride <b>12</b>, EDCI.HCl, triethylamine, DMF, 0 °C to rt, overnight.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0010.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Quinoline and Quinazoline Derivatives II<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) POCl<sub>3</sub>, cat. DMF, reflux; (b) 3-ethynylphenylamine, cat. conc HCl, isopropyl alcohol, reflux.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Proposed binding mode of 4-anilinoquinolines to EGFR. (a) <b>3e</b> is modeled into the ATP-binding site of EGFR based on the crystal structure of Erlotinib in complex with EGFR (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>) and an irreversible quinazoline in complex with cSrc (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QLQ">2QLQ</a>). The ring nitrogen of the quinoline forms a hydrogen bond (red dotted line) with the backbone of the hinge region (pink). The protonated tertiary amine of <b>3e</b> is within hydrogen bonding distance to the side chain of Asp800. This additional interaction is not observed for different substituted quinolines and helps to explain the gain in affinity for <b>3e</b>. (b) The irreversible 4-anilinoquinoline <b>3a</b> is modeled into the ATP-binding site of EGFR based on the crystal structure of its quinazoline counterpart to EGFR (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J5F">2J5F</a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The electrophile of the inhibitor forms a covalent bond to the side chain of Cys797.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. 4-Anilinoquinolines inhibit growth of EGFR-dependent cancer cells. (a) GI<sub>50</sub> values for 4-anilinoquinoline- and 4-anilinoquinazoline-based EGFR inhibitors screened against Ba/F3 cell lines expressing different EGFR mutants with or without the secondary Thr790Met gatekeeper mutation (TM). The range of compound activity is color-coded. (b) The EGFR mutant NSCLC cell line PC9 was treated with increasing concentrations of <b>3a</b> (irreversible) and <b>3e</b> (reversible), and cell viability was determined using measurement of ATP content. The error bars represent the standard deviation for three replicates. (c) The NSCLC cell line H1975 expressing the Thr790Met EGFR gatekeeper mutation was treated with increasing concentrations of <b>3a</b> and <b>3e</b>, and cell viability was determined using measurement of ATP content. The error bars represent the standard deviation for three replicates. (d) Inhibition of the activation status of EGFR was determined by immunoblotting after treatment of PC9 cells with increasing concentrations of <b>3a</b> and <b>3e</b> (from left to right: control, 0.1, 0.3, 1, 3, 10 μM); actin was detected as loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/medium/jm-2009-01877j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinase selectivity profile of <b>3e</b> and <b>3f</b>. Kinase profiling was performed for <b>3e</b> and <b>3f</b> against a panel of 95 different protein kinases at a concentration of 10 μM (National Centre for Protein Kinase Profiling, University of Dundee, UK). The screening was carried out using a radioactive (<sup>33</sup>P-ATP) filter-binding assay. The scores represent the % activity remaining relative to the 100% DMSO controls. The inhibition is color coded from red (strong inhibition, low score) to green (weak inhibition, high score). Both quinazoline- and quinoline-based inhibitors show preference for kinases with a small amino acid at the gatekeeper position (Thr).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-7/jm901877j/production/images/large/jm-2009-01877j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901877j&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 26 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhhgC6q1NF1Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1517%2F17460440802579975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=23506106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1409-1425&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinases.+Part+I%3A+exceptions+from+the+traditional+pharmacophore+approach+of+type+I+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span></div><div class="casAuthors">Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Mueller, G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-1425</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Protein kinases are essential enzymes propagating cellular signal transduction processes and consequently have emerged as central targets for drug discovery against a wide range of diseases with a strong historical focus on oncol. disorders.  A large no. of high-resoln. crystal structures of various ATP-competitive inhibitors in complex with their target protein kinases have been detd. and present a wealth of detailed information about binding modes, inhibition mechanisms and assocd. structure-activity relationships of target-bound small mols.  Objective: In this first part of a two-part review, exceptions to the type I binding mode of kinase inhibitors that follow the traditional pharmacophore model are discussed, highlighting unexpected structural features.  Methods: The scope of this review covers published crystal structures of protein kinases in complex with various ligands.  Results: Structural parameters of both inhibitors and kinases contribute to the complexity of designing kinase inhibitors.  The continued study of high-resoln. structures of ligand-enzyme complexes in combination with a more dynamic understanding of accessible conformational states of the target proteins, supported by detailed kinetic studies, will in the long-term help in developing new low-mol. wt. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxVqECguWJbVg90H21EOLACvtfcHk0lhhgC6q1NF1Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D&md5=705fa7e531ceced90ed86d0d2658766e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1517%2F17460440802579975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460440802579975%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinases.%2520Part%2520I%253A%2520exceptions%2520from%2520the%2520traditional%2520pharmacophore%2520approach%2520of%2520type%2520I%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1409%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1427-1449&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinase.+Part+II%3A+the+novel+pharmacophore+approach+of+type+II+and+type+III+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinase.%2520Part%2520II%253A%2520the%2520novel%2520pharmacophore%2520approach%2520of%2520type%2520II%2520and%2520type%2520III%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1427%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 5. Synthesis and structure−activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3487</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00018a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3482-3487&author=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=A.+J.+Bridgesauthor=H.+R.+Zhouauthor=D.+R.+Codyauthor=A.+McMichaelauthor=D.+W.+Fry&title=Tyrosine+kinase+inhibitors.+5.+Synthesis+and+structure%E2%88%92activity+relationships+for+4-%5B%28phenylmethyl%29amino%5D-+and+4-%28phenylamino%29quinazolines+as+potent+adenosine+5%E2%80%B2-triphosphate+binding+site+inhibitors+of+the+tyrosine+kinase+domain+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm00018a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00018a008%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%2BR.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%25205.%2520Synthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520for%25204-%255B%2528phenylmethyl%2529amino%255D-%2520and%25204-%2528phenylamino%2529quinazolines%2520as%2520potent%2520adenosine%25205%25E2%2580%25B2-triphosphate%2520binding%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3482%26epage%3D3487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span> </span><span class="NLM_article-title">4-Anilino-6,7-dialkoxyquinolime-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3244</span><span class="NLM_x">–</span> <span class="NLM_lpage">3256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000206a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3244-3256&author=A.+Wissnerauthor=D.+M.+Bergerauthor=D.+H.+Boschelliauthor=M.+B.+Floydauthor=L.+M.+Greenbergerauthor=B.+C.+Gruberauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=R.+Nilakantanauthor=M.+F.+Reichauthor=R.+Shenauthor=H.+R.+Tsouauthor=E.+Upeslacisauthor=Y.+F.+Wangauthor=B.+Q.+Wuauthor=F.+Yeauthor=N.+Zhang&title=4-Anilino-6%2C7-dialkoxyquinolime-3-carbonitrile+inhibitors+of+epidermal+growth+factor+receptor+kinase+and+their+bioisosteric+relationship+to+the+4-anilino-6%2C7-dialkoxyquinazoline+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm000206a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000206a%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DUpeslacis%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWu%26aufirst%3DB.%2BQ.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DN.%26atitle%3D4-Anilino-6%252C7-dialkoxyquinolime-3-carbonitrile%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520and%2520their%2520bioisosteric%2520relationship%2520to%2520the%25204-anilino-6%252C7-dialkoxyquinazoline%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3244%26epage%3D3256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">The development of HKI-272 and related compounds for the treatment of cancer</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1002%2Fardp.200800009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=18493974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2008&pages=465-477&author=A.+Wissnerauthor=T.+S.+Mansour&title=The+development+of+HKI-272+and+related+compounds+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The development of HKI-272 and related compounds for the treatment of cancer</span></div><div class="casAuthors">Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">465-477</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of HKI-272 and EKB-569 for the treatment of cancer is described.  These compds. function as irreversible inhibitors of some members of the ErbB family of receptor tyrosine kinases.  In particular, they target epidermal growth factor receptor (EGFR, also known as ErbB-1) and human epidermal growth factor receptor-2 (HER2, also known as ErbB-2).  Both, HKI-272 and EKB-569 are 4-anilino-3-cyano quinoline derivs. that contain a 4-(dimethylamino)crotonamide Michael-acceptor group at the 6-position.  These compds. inhibit the function of the target enzymes by forming a covalent interaction with a conserved cysteine residue located in the kinase domains of these proteins.  The potential advantages of using irreversible inhibitors for this purpose are discussed.  We summarize the recent findings concerning some somatic mutations in EGFR and their relevance with respect to the irreversible inhibitors.  In particular, we highlight the findings that these irreversible inhibitors retain activity against tumors that have acquired a resistance to the reversible binding inhibitors gefitinib and erlotinib.  The promising interim clin. trial results for HKI-272 and EKB-569 in treating colon, lung, and breast cancers are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSokM42ZhprVg90H21EOLACvtfcHk0ljIuM5SKzoW7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E&md5=2e46d99ca74e297e6a7e860634bf096d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fardp.200800009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200800009%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DThe%2520development%2520of%2520HKI-272%2520and%2520related%2520compounds%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DArch.%2520Pharm.%26date%3D2008%26volume%3D341%26spage%3D465%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Å resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0ljIuM5SKzoW7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterbein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, G.</span><span> </span><span class="NLM_article-title"><i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6465</span><span class="NLM_x">–</span> <span class="NLM_lpage">6488</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060434q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6465-6488&author=L.+F.+Hennequinauthor=J.+Allenauthor=J.+Breedauthor=J.+Curwenauthor=M.+Fennellauthor=T.+P.+Greenauthor=C.+Lambert-van+der+Bremptauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Olivierauthor=L.+Otterbeinauthor=P.+A.+Pleauthor=N.+Warinauthor=G.+Costello&title=N-%285-Chloro-1%2C3-benzodioxol-4-yl%29-7-%5B2-%284-methylpiperazin-1-yl%29ethoxy%5D-5-+%28tetrahydro-2H-pyran-4-yloxy%29quinazolin-4-amine%2C+a+novel%2C+highly+selective%2C+orally+available%2C+dual-specific+c-Src%2FAbl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm060434q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060434q%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DOtterbein%26aufirst%3DL.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DWarin%26aufirst%3DN.%26aulast%3DCostello%26aufirst%3DG.%26atitle%3DN-%25285-Chloro-1%252C3-benzodioxol-4-yl%2529-7-%255B2-%25284-methylpiperazin-1-yl%2529ethoxy%255D-5-%2520%2528tetrahydro-2H-pyran-4-yloxy%2529quinazolin-4-amine%252C%2520a%2520novel%252C%2520highly%2520selective%252C%2520orally%2520available%252C%2520dual-specific%2520c-Src%252FAbl%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6465%26epage%3D6488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Rachid, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahimi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jean-Claude, B. J.</span><span> </span><span class="NLM_article-title">Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure−activity relationship</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2605</span><span class="NLM_x">–</span> <span class="NLM_lpage">2608</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070144p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2605-2608&author=Z.+Rachidauthor=F.+Brahimiauthor=Q.+Qiuauthor=C.+Williamsauthor=J.+M.+Hartleyauthor=J.+A.+Hartleyauthor=B.+J.+Jean-Claude&title=Novel+nitrogen+mustard-armed+combi-molecules+for+the+selective+targeting+of+epidermal+growth+factor+receptor+overexperessing+solid+tumors%3A+Discovery+of+an+unusual+structure%E2%88%92activity+relationship"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm070144p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070144p%26sid%3Dliteratum%253Aachs%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DBrahimi%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DHartley%26aufirst%3DJ.%2BM.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DNovel%2520nitrogen%2520mustard-armed%2520combi-molecules%2520for%2520the%2520selective%2520targeting%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520overexperessing%2520solid%2520tumors%253A%2520Discovery%2520of%2520an%2520unusual%2520structure%25E2%2588%2592activity%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2605%26epage%3D2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingalls, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nittoli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loganzo, F.</span><span> </span><span class="NLM_article-title">Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3635</span><span class="NLM_x">–</span> <span class="NLM_lpage">3648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=3635-3648&author=A.+Wissnerauthor=H.+L.+Fraserauthor=C.+L.+Ingallsauthor=R.+G.+Dushinauthor=M.+B.+Floydauthor=K.+Cheungauthor=T.+Nittoliauthor=M.+R.+Raviauthor=X.+Z.+Tanauthor=F.+Loganzo&title=Dual+irreversible+kinase+inhibitors%3A+quinazoline-based+inhibitors+incorporating+two+independent+reactive+centers+with+each+targeting+different+cysteine+residues+in+the+kinase+domains+of+EGFR+and+VEGFR-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DFraser%26aufirst%3DH.%2BL.%26aulast%3DIngalls%26aufirst%3DC.%2BL.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DNittoli%26aufirst%3DT.%26aulast%3DRavi%26aufirst%3DM.%2BR.%26aulast%3DTan%26aufirst%3DX.%2BZ.%26aulast%3DLoganzo%26aufirst%3DF.%26atitle%3DDual%2520irreversible%2520kinase%2520inhibitors%253A%2520quinazoline-based%2520inhibitors%2520incorporating%2520two%2520independent%2520reactive%2520centers%2520with%2520each%2520targeting%2520different%2520cysteine%2520residues%2520in%2520the%2520kinase%2520domains%2520of%2520EGFR%2520and%2520VEGFR-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D3635%26epage%3D3648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Michalczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3488</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1016%2Fj.bmc.2008.02.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=18316192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3482-3488&author=A.+Michalczykauthor=S.+Kl%C3%BCterauthor=H.+B.+Rodeauthor=J.+R.+Simardauthor=C.+Gr%C3%BCtterauthor=M.+Rabillerauthor=D.+Rauh&title=Structural+insights+into+how+irreversible+inhibitors+can+overcome+drug+resistance+in+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span></div><div class="casAuthors">Michalczyk, Anja; Klueter, Sabine; Rode, Haridas B.; Simard, Jeffrey R.; Gruetter, Christian; Rabiller, Matthias; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3482-3488</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Resistance to kinase-targeted cancer drugs has recently been linked to a single point mutation in the ATP binding site of the kinase.  In EGFR, the crucial Thr790 gatekeeper residue is mutated to a Met and prevents reversible ATP competitive inhibitors from binding.  Irreversible 4-(phenylamino)quinazolines have been shown to overcome this drug resistance and are currently in clin. trials.  In order to obtain a detailed structural understanding of how irreversible inhibitors overcome drug resistance, the authors used Src kinase as a model system for drug resistant EGFR-T790M.  The authors report the first crystal structure of a drug resistant kinase in complex with an irreversible inhibitor.  This 4-(phenylamino)quinazoline inhibits wild type and drug resistant EGFR in vitro at low nM concns.  The cocrystal structure of drug resistant cSrc-T338M kinase domain provides the structural basis of this activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp52JtORqsX7Vg90H21EOLACvtfcHk0lhazsiJmQKEYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gruro%253D&md5=b9fc704067e495279bad4913e9c703ab</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.053%26sid%3Dliteratum%253Aachs%26aulast%3DMichalczyk%26aufirst%3DA.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructural%2520insights%2520into%2520how%2520irreversible%2520inhibitors%2520can%2520overcome%2520drug%2520resistance%2520in%2520EGFR%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D3482%26epage%3D3488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">11011</span><span class="NLM_x">–</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1073%2Fpnas.0504952102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=16046538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnvVWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span></div><div class="casAuthors">Carter, Todd A.; Wodicka, Lisa M.; Shah, Neil P.; Velasco, Anne Marie; Fabian, Miles A.; Treiber, Daniel K.; Milanov, Zdravko V.; Atteridge, Corey E.; Biggs, William H., III; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Mehta, Shamal A.; Patel, Hitesh K.; Pao, William; Sawyers, Charles L.; Varmus, Harold; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11011-11016</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it is important to address the emergence of drug resistance in treated patients.  Mutant forms of BCR-ABL, KIT, and the EGF receptor (EGFR) have been found that confer resistance to the drugs imatinib, gefitinib, and erlotinib.  The mutations weaken or prevent drug binding, and interestingly, one of the most common sites of mutation in all three kinases is a highly conserved "gatekeeper" threonine residue near the kinase active site.  We have identified existing clin. compds. that bind and inhibit drug-resistant mutant variants of ABL, KIT, and EGFR.  We found that the Aurora kinase inhibitor VX-680 and the p38 inhibitor BIRB-796 inhibit the imatinib- and BMS-354825-resistant ABL(T315I) kinase.  The KIT/FLT3 inhibitor SU-11248 potently inhibits the imatinib-resistant KIT(V559D/T670I) kinase, consistent with the clin. efficacy of SU-11248 against imatinib-resistant gastrointestinal tumors, and the EGFR inhibitors EKB-569 and Cl-1033, but not GW-572016 and ZD-6474, potently inhibit the gefitinib- and erlotinib-resistant EGFR(L858R/T790M) kinase.  EKB-569 and Cl-1033 are already in clin. trials, and our results suggest that they should be considered for testing in the treatment of gefitinib/erlotinib-resistant non-small cell lung cancer.  The results highlight the strategy of screening existing clin. compds. against newly identified drug-resistant mutant variants to find compds. that may serve as starting points for the development of next-generation drugs, or that could be used directly to treat patients that have acquired resistance to first-generation targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdgFgcC03tybVg90H21EOLACvtfcHk0ljnECXeRVdMag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnvVWjurg%253D&md5=448c95c51b0cf9b5035df4065cd8f62c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0504952102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0504952102%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2005%26volume%3D102%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=225-235&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D225%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljnECXeRVdMag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robubi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3915</span><span class="NLM_x">–</span> <span class="NLM_lpage">3926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9002928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3915-3926&author=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=J.+R.+Simardauthor=S.+Kl%C3%BCterauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=A.+Robubiauthor=D.+Rauh&title=Hybrid+compound+design+to+overcome+the+gatekeeper+T338M+mutation+in+cSrc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc</span></div><div class="casAuthors">Getlik, Matthaeus; Gruetter, Christian; Simard, Jeffrey R.; Kluter, Sabine; Rabiller, Matthias; Rode, Haridas B.; Robubi, Armin; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3915-3926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments.  Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance.  Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed to develop these scaffolds into potent type II kinase inhibitors.  One of these compds., I (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc.  Details gleaned from crystal structures revealed a key feature of a subset of these compds., a surprising flexibility in the vicinity of the gatekeeper residue that allows these compds. to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-72ZDo25pC7Vg90H21EOLACvtfcHk0ljnECXeRVdMag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D&md5=3ff187e49298ec4690c76a2bc2100274</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002928%26sid%3Dliteratum%253Aachs%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRobubi%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHybrid%2520compound%2520design%2520to%2520overcome%2520the%2520gatekeeper%2520T338M%2520mutation%2520in%2520cSrc%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3915%26epage%3D3926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation from chemo-genomics profiling</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=859-862&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=J.+Y.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Insights+into+the+limited+activity+of+irreversible+EGFR+inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation+from+chemo-genomics+profiling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%2520from%2520chemo-genomics%2520profiling%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D859%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, E. S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span> </span><span class="NLM_article-title">Design and structure−activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">5369</span><span class="NLM_x">–</span> <span class="NLM_lpage">5389</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990345w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=5369-5389&author=L.+F.+Hennequinauthor=A.+P.+Thomasauthor=C.+Johnstoneauthor=E.+S.+E.+Stokesauthor=P.+A.+Pleauthor=J.+J.+M.+Lohmannauthor=D.+J.+Ogilvieauthor=M.+Dukesauthor=S.+R.+Wedgeauthor=J.+O.+Curwenauthor=J.+Kendrewauthor=C.+Lambert-van+der+Brempt&title=Design+and+structure%E2%88%92activity+relationship+of+a+new+class+of+potent+VEGF+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm990345w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990345w%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DStokes%26aufirst%3DE.%2BS.%2BE.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DLohmann%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26atitle%3DDesign%2520and%2520structure%25E2%2588%2592activity%2520relationship%2520of%2520a%2520new%2520class%2520of%2520potent%2520VEGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D5369%26epage%3D5389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Furuta, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, A.</span><span> </span><span class="NLM_article-title">Identification of potent and selective inhibitors of PDGF receptor autophosphorylation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2186</span><span class="NLM_x">–</span> <span class="NLM_lpage">2192</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0506423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2186-2192&author=T.+Furutaauthor=T.+Sakaiauthor=T.+Sengaauthor=T.+Osawaauthor=K.+Kuboauthor=T.+Shimizuauthor=R.+Suzukiauthor=T.+Yoshinoauthor=M.+Endoauthor=A.+Miwa&title=Identification+of+potent+and+selective+inhibitors+of+PDGF+receptor+autophosphorylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm0506423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0506423%26sid%3Dliteratum%253Aachs%26aulast%3DFuruta%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DOsawa%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DEndo%26aufirst%3DM.%26aulast%3DMiwa%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520PDGF%2520receptor%2520autophosphorylation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2186%26epage%3D2192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naquvi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Design of a displacement assay for kinases based on a DFG-out binding probe</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=357-367&author=S.+Kl%C3%BCterauthor=C.+Gr%C3%BCtterauthor=T.+Naquviauthor=M.+Rabillerauthor=J.+R.+Simardauthor=V.+Pawarauthor=M.+Getlikauthor=D.+Rauh&title=Design+of+a+displacement+assay+for+kinases+based+on+a+DFG-out+binding+probe"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DNaquvi%26aufirst%3DT.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DDesign%2520of%2520a%2520displacement%2520assay%2520for%2520kinases%2520based%2520on%2520a%2520DFG-out%2520binding%2520probe%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D53%26spage%3D357%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPietro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, R.</span><span> </span><span class="NLM_article-title">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1667</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701097z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1649-1667&author=J.-C.+Harmangeauthor=M.+M.+Weissauthor=J.+Germainauthor=A.+J.+Polverinoauthor=G.+Borgauthor=J.+Breadyauthor=D.+Chenauthor=D.+Choquetteauthor=A.+Coxonauthor=T.+DeMelfiauthor=L.+DiPietroauthor=N.+Doerrauthor=J.+Estradaauthor=J.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=S.+Kaufmanauthor=D.+S.+Laauthor=A.+Longauthor=M.+W.+Martinauthor=S.+Neervannanauthor=V.+F.+Patelauthor=M.+Potashmanauthor=K.+Regalauthor=P.+M.+Rovetoauthor=M.+L.+Schragauthor=C.+Starnesauthor=A.+Taskerauthor=Y.+Tefferaauthor=L.+Wangauthor=R.+D.+Whiteauthor=D.+A.+Whittingtonauthor=R.+Zanon&title=Naphthamides+as+Novel+and+Potent+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors%3A+Design%2C+Synthesis%2C+and+Evaluation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation</span></div><div class="casAuthors">Harmange, Jean-Christophe; Weiss, Matthew M.; Germain, Julie; Polverino, Anthony J.; Borg, George; Bready, James; Chen, Danlin; Choquette, Deborah; Coxon, Angela; DeMelfi, Tom; DiPietro, Lucian; Doerr, Nicholas; Estrada, Juan; Flynn, Julie; Graceffa, Russell F.; Harriman, Shawn P.; Kaufman, Stephen; La, Daniel S.; Long, Alexander; Martin, Matthew W.; Neervannan, Sesha; Patel, Vinod F.; Potashman, Michele; Regal, Kelly; Roveto, Phillip M.; Schrag, Michael L.; Starnes, Charlie; Tasker, Andrew; Teffera, Yohannes; Wang, Ling; White, Ryan D.; Whittington, Douglas A.; Zanon, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1649-1667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of naphthyl-based compds. were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors.  Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family.  Numerous analogs demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compds. possessed favorable pharmacokinetic (PK) profiles.  In particular, compd. I demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice.  A full account of the prepn., structure-activity relationships, pharmacokinetic properties, and pharmacol. of analogs within this series is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1vrmtgp3_m7Vg90H21EOLACvtfcHk0li-C-Rf9-jTkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D&md5=25685f28450b2ab132ffd278e6c53598</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm701097z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701097z%26sid%3Dliteratum%253Aachs%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DBorg%26aufirst%3DG.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDiPietro%26aufirst%3DL.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLong%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DSchrag%26aufirst%3DM.%2BL.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZanon%26aufirst%3DR.%26atitle%3DNaphthamides%2520as%2520Novel%2520and%2520Potent%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1649%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Bridges, A. J.; Denny, W. A.; Dobrusin, E. M.; Doherty, A. M.; Fry, D. W.; McNamara, D. J.; Showalter, H. D. H.; Smaill, J. B.; Zhou, H.</span><span class="NLM_etal">et al.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors</span>. U.S. Patent 97-US5778 9738983, 19970408,<span class="NLM_x"> </span><span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=A.+J.+Bridges&author=W.+A.+Denny&author=E.+M.+Dobrusin&author=A.+M.+Doherty&author=D.+W.+Fry&author=D.+J.+McNamara&author=H.+D.+H.+Showalter&author=J.+B.+Smaill&author=H.+Zhou&title=Preparation+of+N-quinazolinylacrylamides+and+analogs+as+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26atitle%3DPreparation%2520of%2520N-quinazolinylacrylamides%2520and%2520analogs%2520as%2520tyrosine%2520kinase%2520inhibitors%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frommolt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuckrath, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beroukhim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winckler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFramboise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahnenfuhrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhaak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=1727-1740&author=M.+L.+Sosauthor=K.+Michelauthor=T.+Zanderauthor=J.+Weissauthor=P.+Frommoltauthor=M.+Peiferauthor=D.+Liauthor=R.+Ullrichauthor=M.+Kokerauthor=F.+Fischerauthor=T.+Shimamuraauthor=D.+Rauhauthor=C.+Mermelauthor=S.+Fischerauthor=I.+Stuckrathauthor=S.+Heynckauthor=R.+Beroukhimauthor=W.+Linauthor=W.+Wincklerauthor=K.+Shahauthor=T.+LaFramboiseauthor=W.+F.+Moriartyauthor=M.+Hannaauthor=L.+Tolosiauthor=J.+Rahnenfuhrerauthor=R.+Verhaakauthor=D.+Chiangauthor=G.+Getzauthor=M.+Hellmichauthor=J.+Wolfauthor=L.+Girardauthor=M.+Peytonauthor=B.+A.+Weirauthor=T.+H.+Chenauthor=H.+Greulichauthor=J.+Barretinaauthor=G.+I.+Shapiroauthor=L.+A.+Garrawayauthor=A.+F.+Gazdarauthor=J.+D.+Minnaauthor=M.+Meyersonauthor=K.+K.+Wongauthor=R.+K.+Thomas&title=Predicting+drug+susceptibility+of+non-small+cell+lung+cancers+based+on+genetic+lesions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DMichel%26aufirst%3DK.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DFrommolt%26aufirst%3DP.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DUllrich%26aufirst%3DR.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DStuckrath%26aufirst%3DI.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DMoriarty%26aufirst%3DW.%2BF.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DTolosi%26aufirst%3DL.%26aulast%3DRahnenfuhrer%26aufirst%3DJ.%26aulast%3DVerhaak%26aufirst%3DR.%26aulast%3DChiang%26aufirst%3DD.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DHellmich%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DPredicting%2520drug%2520susceptibility%2520of%2520non-small%2520cell%2520lung%2520cancers%2520based%2520on%2520genetic%2520lesions%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D1727%26epage%3D1740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glatt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.4161%2Fcbt.6.5.4003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=17495523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyrsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=661-667&author=Y.+Yuzaauthor=K.+A.+Glattauthor=J.+R.+Jiangauthor=H.+Greulichauthor=Y.+Minamiauthor=M.+S.+Wooauthor=T.+Shimamuraauthor=G.+Shapiroauthor=J.+C.+Leeauthor=H.+B.+Jiauthor=W.+Fengauthor=T.+H.+Chenauthor=H.+Yanagisawaauthor=K.+K.+Wongauthor=M.+Meyerson&title=Allele-dependent+variation+in+the+relative+cellular+potency+of+distinct+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors</span></div><div class="casAuthors">Yuza, Yuki; Glatt, Karen A.; Jiang, Jingrui; Greulich, Heidi; Minami, Yuko; Woo, Michele S.; Shimamura, Takeshi; Shapiro, Geoffrey; Lee, Jeffrey C.; Ji, Hongbin; Feng, Whei; Chen, Tzu-Hsiu; Yanagisawa, Haruhiko; Wong, Kwok-Kin; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">661-667</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Targeted cancer therapies impede cancer cell growth by inhibiting the function of activated oncogene products.  Patients with non-small cell lung cancer and somatic mutations of EGFR can have a dramatic response to treatment with erlotinib and gefitinib; different somatic mutations are assocd. with different times to progression and survival.  In this study, the relative and abs. potencies of two distinct EGFR tyrosine kinase inhibitors, erlotinib and an investigational irreversible inhibitor, HKI-272, were found to vary significantly in a panel of Ba/F3 cells transformed by representative EGFR somatic mutations.  HKI-272 more potently inhibited the primary exon 20 insertion mutants, the secondary erlotinib-resistance mutants including T790M and many erlotinib-sensitive mutants including L858R.  In contrast, erlotinib is a more potent inhibitor of the major exon 19 deletion mutants than is HKI-272.  Analyses of EGFR autophosphorylation patterns confirmed the mutation-specific variation in relative potency of these tyrosine kinase inhibitors.  Our finding that distinct EGFR inhibitors are more effective in vitro for different mutant forms of the protein suggests that tyrosine kinase inhibitor treatment could be tailored to specific EGFR mutations.  More broadly, these results imply that the development and deployment of targeted therapies should focus on inhibition of specific cancer-causing mutations, not only on the mutated target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQZ-_1zRKrsrVg90H21EOLACvtfcHk0liVzDANaVifiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyrsrvM&md5=1be5784f5c44158dc72af4476ca46d67</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.4161%2Fcbt.6.5.4003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.6.5.4003%26sid%3Dliteratum%253Aachs%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DGlatt%26aufirst%3DK.%2BA.%26aulast%3DJiang%26aufirst%3DJ.%2BR.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DJi%26aufirst%3DH.%2BB.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DYanagisawa%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DAllele-dependent%2520variation%2520in%2520the%2520relative%2520cellular%2520potency%2520of%2520distinct%2520EGFR%2520inhibitors%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D661%26epage%3D667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frommolt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashkar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3256</span><span class="NLM_x">–</span> <span class="NLM_lpage">3261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3256-3261&author=M.+L.+Sosauthor=M.+Kokerauthor=B.+A.+Weirauthor=S.+Heynckauthor=R.+Rabinovskyauthor=T.+Zanderauthor=J.+M.+Seegerauthor=J.+Weissauthor=F.+Fischerauthor=P.+Frommoltauthor=K.+Michelauthor=M.+Peiferauthor=C.+Mermelauthor=L.+Girardauthor=M.+Peytonauthor=A.+F.+Gazdarauthor=J.+D.+Minnaauthor=L.+A.+Garrawayauthor=H.+Kashkarauthor=W.+Paoauthor=M.+Meyersonauthor=R.+K.+Thomas&title=PTEN+Loss+Contributes+to+Erlotinib+Resistance+in+EGFR-Mutant+Lung+Cancer+by+Activation+of+Akt+and+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DRabinovsky%26aufirst%3DR.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DSeeger%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DFrommolt%26aufirst%3DP.%26aulast%3DMichel%26aufirst%3DK.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DKashkar%26aufirst%3DH.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DPTEN%2520Loss%2520Contributes%2520to%2520Erlotinib%2520Resistance%2520in%2520EGFR-Mutant%2520Lung%2520Cancer%2520by%2520Activation%2520of%2520Akt%2520and%2520EGFR%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D3256%26epage%3D3261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm901877j&amp;key=10.1038%2Fnchembio866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm901877j&amp;key=17334377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm901877j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=229-238&author=J.+A.+Blairauthor=D.+Rauhauthor=C.+Kungauthor=C.+H.+Yunauthor=Q.+W.+Fanauthor=H.+Rodeauthor=C.+Zhangauthor=M.+J.+Eckauthor=W.+A.+Weissauthor=K.+M.+Shokat&title=Structure-guided+development+of+affinity+probes+for+tyrosine+kinases+using+chemical+genetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span></div><div class="casAuthors">Blair, Jimmy A.; Rauh, Daniel; Kung, Charles; Yun, Cai-Hong; Fan, Qi-Wen; Rode, Haridas; Zhang, Chao; Eck, Michael J.; Weiss, William A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-mol. inhibitors.  The authors report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue.  Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Cocrystal structures of two irreversible quinazoline inhibitors (I, II) bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Based on these structures, the authors developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe (III) to report the fraction of kinase necessary for cellular signaling, and the authors used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0KmYAm-skrVg90H21EOLACvtfcHk0lgiUA4M4EtztA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D&md5=ce4d24a8d65d7080645bf382cd65dbca</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio866%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DFan%26aufirst%3DQ.%2BW.%26aulast%3DRode%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DStructure-guided%2520development%2520of%2520affinity%2520probes%2520for%2520tyrosine%2520kinases%2520using%2520chemical%2520genetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17','PDB','1M17'); return false;">PDB: 1M17</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV','PDB','2JIV'); return false;">PDB: 2JIV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QQ7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QQ7','PDB','2QQ7'); return false;">PDB: 2QQ7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QLQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QLQ','PDB','2QLQ'); return false;">PDB: 2QLQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J5F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J5F','PDB','2J5F'); return false;">PDB: 2J5F</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i29"><a href="/doi/suppl/10.1021/jm901877j">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_22310"></div></div></div></div></div><hr /></hr><p class="last">Figure and experimental data for compounds <b>7</b>, <b>8a</b>, <b>11a</b>, <b>15a</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901877j/suppl_file/jm901877j_si_001.pdf">jm901877j_si_001.pdf (292.85 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm901877j&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-7%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm901877j%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm901877j" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6a73193723f8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
